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A brief history of pediatric critical care medicine 
 
Pediatric critical care is a new discipline in medicine, emerging only 60 years ago.(1) 
Five crucial developments in the 1950’s were essential for the development of pediatric critical care 
medicine, namely the polio epidemic, the respiratory distress syndrome and breakthroughs in pediatric 
anesthesiology, surgery and cardiac surgery. The polio epidemic led to the development of the mechanical 
ventilators. It was Dr. Ibsen in Copenhagen who took the initiative to ventilate patients manually after they 
underwent a tracheotomy and received rubber cuff tubes.(2) He organized a special unit for respiratory care 
where he employed nurses, medical students and technicians to work around the clock. Thanks to their 
efforts polio-related mortality decreased from 90% to 40%. These special units also cared for children, but 
they quickly understood that children needed separate units. In 1955 Dr. G Haglund in Goteburg, Sweden 
founded the first pediatric ICU.(3) 
The understanding of the infant respiratory distress syndrome and its treatment with surfactant led in 1960 
to the survival of children with chronic lung disease, termed bronchopulmonary dysplasia. These children 
needed pediatric intensive care after their discharge from neonatology. 
Dr. E Koop, was a brilliant and courageous pediatric surgeon who pioneered many surgical techniques in 
the 1950’s and was the first to create a special postsurgical care unit for children in Children’s Hospital of 
Philadelphia (CHOP). Together with Dr. W Rashkind (father of the interventional pediatric cardiology), Dr. J 
Waldhausen (one of the first full time pediatric cardiac surgeons), Dr. Sylvan Stool (a pioneer in pediatric 
otolaryngology) they further developed this unit.  
The first extra cardiac shunt between the subclavian artery and the ipsilateral pulmonary artery was 
performed the first in the John Hopkins hospital in 1945 by Alfred Blalock, Vivien Thomas and Helen 
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Taussig. The first open-heart surgery on a child with cardiopulmonary bypass was done by J. Gibbon in 
1953. Thanks to the anesthesiologists who transferred their knowledge of pediatric physiology and 
pharmacology these postoperative pediatric critical care units were established and grew over the years. 
The recognition of the subspecialty of pediatric critical care took place in 1981. In 1983 guidelines defining 
the minimal requirements of a PICU became available. Nowadays pediatric critical care medicine is an 
exciting combination of high standard multidisciplinary medicine involving many medical specialties and the 
unique aspect of the patient’s childhood. The pediatric intensivist has to preserve a plan for each of the 
patients in close communication with all stakeholders (parents, specialists, nurses, physiotherapists etc..) 
involved. This complex task is in many ways rewarding but also demanding. 
Due to the technological and medical advances in the following decades, mortality in the PICU has 
significantly declined. But therefore nowaday’s PICU population has also become more complex. Not only 
children with more serious diseases are treated or operated on before being admitted to the PICU. Critically 
ill children are also more often confronted with multiple organ dysfunction and consequently prolonged 
critical illness. The increase in prevalence of prolonged critical illness, hallmarked by intensive care- unit 
acquired weakness (ICUAW), faces the pediatric intensivist with new ethical problems.  
Similar to the shift in adult ICU population, the focus of clinical practice and research should be based on a 
combination of hard clinical outcome measures in the long-term such as 90 mortality, new infections and 
ventilator dependency and of quality of life up to several years after hospital discharge.  
Despite that this is time consuming and most labor-intensive, knowing if and how the critically ill patients 
survive is crucial for all stakeholders from patients to health policy makers. 
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Muscle Wasting 
 
Prolonged critical illness is frequently hallmarked by intensive care unit-acquired weakness (ICUAW). 
ICUAW is typically symmetrical and more pronounced in the proximal muscles than in the distal muscles.(4, 
5) It is related to the severity of illness and the length of stay in ICU. However, ICUAW already starts within 
the first week of critical illness and is associated with functional disability in the longer term. The ICUAW is 
the result of critical illness polyneuropathy (CIP) or critical illness myopathy (CIM) or a combination of both. 
Skeletal muscle wasting is the most typical clinical feature of ICUAW and is due to muscle fiber degradation 
and decreased synthesis. A detailed overview of the molecular mechanisms behind ICUAW has recently 
been published.(6-8) The main risk factors for ICUAW are high severity of illness upon admission, sepsis, 
multiple organ failure, prolonged immobilization, hyperglycemia and older age.(5) 
ICUAW is associated with prolonged mechanical ventilation, longer ICU and hospital stay and increased 
mortality. In the longer-term, it also impairs rehabilitation and recovery, leading to poor quality of life.(9, 10) 
A systematic review indicated that 28% of patents suffered from severe sequellae of ICUAW.(11) 
Unfortunately therapeutic interventions are limited to early mobilization, blood glucose control, aggressive 
treatment of sepsis and limiting the use of glucocorticoids and neuromuscular blocking agents.(11, 12) 
ICUAW is poorly described in children.(13) It is more difficult to diagnose, as strength measurements are 
only possible and validated from the age of 6 onwards. These muscle strength measurements, such as the 
Medical Research Council (MRC)-SUM test, are the gold standard for diagnosing ICUAW.(14) However, 
these tests require cooperative patients and thus cannot be applied in sedated children or infants.   
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Quantification of muscle wasting 
 
Due to the lack of therapeutic options and the important long-term consequences of ICUAW and muscle 
wasting, their early detection may be essential to steer risk stratification and preventative measures. 
Assessment of limb muscle strength by functional, volitional measurements, such as the Medical Research 
Council (MRC)-sum score and handgrip strength, is the gold standard.(15) However, only fully awake and 
cooperative patients can undergo these measurements, potentially causing a delay in the diagnosis of 
ICUAW.(10) Therefore, non-volitional muscle strength measurements, such as an electromyogram to detect 
critical illness polyneuropathy and myopathy, have been used for the early screening for ICUAW. 
Unfortunately, this technique is complex, requiring expert’s interpretation.(12) 
Ultrasound measurements of muscle thickness are also considered to be a non-volitional surrogate for 
muscle strength.(16) The use of ultrasonography is well integrated in daily ICU-practice. In comparison with 
computer tomography (CT) and magnetic resonance imaging (MRI), ultrasound measurements of muscle 
thickness are inexpensive and logistically less cumbersome. When using a strict imaging protocol, the 
ultrasound measurements correlate well with the CT and MRI measurements.(10, 16, 17) In adult critically ill 
patients ultrasound measurements of m. quadriceps femoris muscle thickness were sensitive to detect a 
decrease in muscle mass in patients with a prolonged ICU-stay.(6) In a recent prospective, 
ultrasonographical evaluation of muscle wasting in critically ill patients, rectus femoris cross-sectional area 
was decreased by approximately 18% at day 10.(18) The recent paper of Tilluist et al. highlighted the 
reliability of bedside ultrasound in assessing muscle thickness in healthy volunteers.(19)  
However ICUAW is poorly characterized in children, with only case reports as evidence(13, 20). Neither the 
functional, volitional measurements of muscle strength nor the non-volitional measurements of muscle 
mass, such as ultrasonography have been validated in the pediatric critically ill patient population. 
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Additionally, ultrasonographical measurements of muscle mass are harder to standardize due to the age-
dependency of muscle mass.  
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Energy requirements 
 
Metabolic Response To Acute Injury 
 
The common thought has always been that a decreased energy provision to skeletal muscle plays a key 
role in skeletal muscle wasting and ICUAW. Due to acute critical illness, the patient cannot eat normally and 
is thus confronted with caloric deficit, which will build up during ICU-stay. The caloric deficit is a function of 
the patient’s energy requirements and the amount of calories delivered to the patient.  
 
Resting Energy Expenditure 
 
Total energy expenditure is the energy generated by oxidative metabolism and is subdivided in four 
components. The most important component is the basal metabolic rate (BMR) (70% of EE). This is the 
energy needed to sustain all vital processes. The second component is the energy needed for growth (5-
35% of EE, depending on the age of the child). Diet-induced thermogenesis (4-10% of EE) is the third 
component. Physical activity, the forth component, is variable and typically expressed as multiples of BMR.  
Determining the caloric needs of infants and children on the PICU starts with the estimation of the resting 
energy expenditure, as physical activity is minimal. The REE is defined as the amount of calories needed at 
rest during a 24 hour period. It is closely related to the BMR but not exactly the same. The REE can be 
determined either by standard equations or by the use of indirect calorimetry.(21-25) There are many 
equations available to predict the EE in children (Table 1). Their accuracy in critical ill children is however 
not clear. For example the Harris Benedict equation is often used in PICU for children, however the formula 
itself is based on measurements made on 97 infants < 8 days of age and on 239 individuals > 16 years of 
age.(21) The Harris Benedict equation has thus never been validated for children.  
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Despite the common use of these formulas, concordance with energy expenditure has not been shown.  
REE can be measured indirectly with a metabolic cart, using the analysis of expired gases to derive the 
volume of air that passes through the lungs, the amount of oxygen extracted from it (VO2) and the amount 
of carbon dioxide that is produced (VCO2).(26) The latter immediately reveals a major conceptual problem, 
namely that with the use of this technique we can only measure what is produced as CO2. The technique is 
also time consuming. Moreover, when the inspired fraction of oxygen is above 40%, the measurements are 
not reliable, making indirect calorimetry unusable in the sickest children, who often need the highest fraction 
of oxygen. There is also a high variability of results with the different types of indirect calorimeters.(27) The 
many equations available and the limited use of indirect calorimetry lead to wide variations in caloric goals 
used in the PICU worldwide. 
 
Many nutritional experts advocate that correction factors should be used to account for the severity of 
illness, because these experts assume that children who are critically ill need even more nutrition. 
Nevertheless, the latter is not standardized nor supported by high quality research. 
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Table 1  
Harris-Benedict equation (kcal/d) 
Boys: 66.4730 + (5.0033 * height) + (13.7516 * weight) - (6.7550 * age) 
Girls: 655.0955 + (1.8496 * height) + (9.5634 * weight) - (4.6756 * age) 
 
 
 
Schofield equations (kj/d) (1 kcal ¼ 4.186 kj) 
< 3 y   Boys: (0.0007 * weight) + (6.349 * height) - 2.584 
 Girls: (0.068 *weight) + (4.281 * height) - 1.730 
3–10 y  Boys: (0.082 * weight) + (0.545 * height) + 1.736 
 Girls: (0.071 * weight) + (0.677 * height) + 1.553 
10–18 y   Boys: (0.068 * weight) + (0.574 * height) + 2.157 
 Girls: (0.035 * weight) + (1.948 * height) + 0.837 
 
FAO/WHO/UNU equations 
< 3 y    Boys: (kcal/d): (60.9 * weight) - 54 
 Girls: (kcal/d): (61 * weight) - 51 
3–10 y old (1 kcal ¼ 4.186 kJ) 
 Boys: (kJ/g): (95 * weight) + 2071 
 Girls: (kJ/d): (94 * weight) + 2088 
 
10–18 y   Boys: (kcal/d): (16.6 * weight) + (77 * height) + 572 
 Girls (kcal/d): (7.4 * weight) + (482 * height) + 217 
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Maffeis equations (kJ/d) (1 kcal ¼ 4.186 kJ) 
Boys: (28.6 * weight) + (23.6 * height) - (69.1 * age) + 1287 
Girls: (35.8 * weight) + (15.6 * height) - (36.3 * age) + 1552 
 
 
 
Fleisch equation (kcal/d) 
Boys:   1–12 y: 24 * BSA * (54-0.885 * age) 
13–19 y: 24 * BSA * (42.5 - [0.64 * (28)]) 
Girls:   1–10 y: 24 * BSA * (54-1.045 * age) 
11–19 y: 24 * BSA * (42.5 - [0.778 * (28)]) 
BSA, body surface area; FAO/WHO/UNU, Food and Agriculture Organization/ 
World Health Organization/United Nations University;  
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Artificial Nutrition 
 
Critical illness results in anorexia, a caloric deficit, muscle wasting and a profound catabolic response. 
Critical illness is also supposed to give higher energy needs, certainly in the second “flow” phase. In order 
to meet these energy needs and to prevent protein loss , nutrition is initiated by the physician. As most of 
the patients admitted to the PICU are incapable of eating, artificial nutrition is commonly used.  
Artificial nutrition is the combination of macronutrients (lipids, carbohydrates and proteins) and 
micronutrients (vitamins and trace elements). The artificial nutrition can be given directly into the vein 
(parenteral nutrition), or in the gastrointestinal tract (enteral nutrition). 
 
Enteral nutrition 
 
The enteral route is preferred as it has been suggested that feeding via the gut maintains gut integrity and 
may reduce the risk of infection, in comparison with feeding via the parenteral route. The composition of 
enteral nutrition for neonates is based on breast milk. For older children the protein and energy load of 
enteral nutrition is higher. 
The delivery of enteral nutrition in PICU population is challenging, due to intolerance to enteral nutrition. Not 
only commonly administered medications, such as opioids, but also critical illness itself impairs the gastric 
intestinal motility. On top of that the physicians’ treatments, such as fluid restriction and extubation, result in 
frequent interruptions of administration of enteral feeding. 
The timing of EN for critically ill children has mostly been studied in children with burns. An RCT of early 
(within 24 hours) versus conventional (after 48 hours) initiation of EN in 77 children with burns showed no 
effect on either surrogate outcome measures (nitrogen balance, serum (pre)albumin), nor on hard clinical 
outcomes (mortality, sepsis, length of stay) (29). However, in a more recent RCT by Khorasani et al in 688 
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children with burns, early EN (started within 3-6 hours) was associated with a lower mortality rate, shorter 
hospital stay and less weight loss compared to children receiving late EN (after 48 hours) (30). 
Other RCTs on EN in critically ill infants and children mainly focused on the amount of protein. In a number 
of studies in infants and children receiving high protein EN compared to normal diet, protein synthesis and 
plasma levels of essential and branched chain amino acids were increased (31-34). Only one RCT was 
powered to detect clinical outcome parameters and found that survival improved with high protein enteral 
intake in children with burns (35). Children receiving normal protein enteral nutrition also had more 
bacteriemic days and days on antibiotics.  
 
Parenteral Nutrition 
 
The first experiments with parenteral nutrition on dogs date from 1966 (36). Before that time it was difficult 
to achieve intravenous access as sharp metal needles were used and stayed in place. Moreover as the IV 
solutions were given peripherally, they had to be iso-osmotic. This was a second hindrance as this required 
large amounts of fluid in a time when effective IV diuretics were not available. A pioneer study in dogs 
showed however that they could be successfully fed solely parenterally. In 1968 a child got for the first time 
parenteral nutrition. A neonate with small bowel atresia, who was moribund after extensive bowel resection 
and weighted only 1.8 kg, was effectively fed parenterally for 22 months and achieved a maximum weight of 
8.3 kg. Clinicians gained during her treatment essential technical and metabolic insights(37).  
Since the 1970’s parenteral nutrition has been used more routinely in adult and pediatric ICUs. Guidelines 
on how to administer parenteral nutrition during pediatric critical illness have evolved over the following 
decades. As more parenteral nutrition solutions became commercially available, focus was very much on 
the composition of parenteral nutrition (mixture of amino acids, type of lipids). Similar to timing of EN, the 
classically held dogma has been that caloric deficits should be minimized. Parenteral nutrition should be 
used when EN alone cannot meet the child’s caloric needs. The current guidelines on energy requirements 
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in critically ill children and the prevention of caloric deficits are not detailed. The ESPEN (European Society 
for Clinical Nutrition and Metabolism)/ESPGHAN (European Society for Paediatric Gastroenterology 
Hepatology and Nutrition) guidelines state that the initiation of PN depends on the individual circumstances 
and the age and size of the infant or child (3). They advocate starting PN shortly after admission when EN 
fails, but in older children and adolescents longer periods of inadequate nutrition can be tolerated. In brief, 
current age-related recommendations advise glucose infusion for hospitalized children in the range of 2-13 
mg/kg/min and to limit it to around 5 mg/kg/min in critically ill children(6). Protein intake during critical illness 
may be up to 2-3 g/kg/day, dependent on the age, to improve the nitrogen balance (6). The requirements of 
specific amino acid concentrations are still unclear. Free fatty acids remain the primary source of energy 
under inflammatory stress(4). Lipid provision should be 30 % to 40 % of the non-protein calories to a 
maximum of 3-4 g/kg.day in infants and 2-3 g/kg.day in older children. The American A.S.P.E.N. (American 
Society for Parenteral and Enteral Nutrition) guidelines make no recommendations concerning PN on the 
PICU(1). They only state that in older children a caloric deficit can be tolerated for up to a week.  
These recommendations have been mainly based on expert opinion and not on state-of-the-art randomized 
controlled trials. Surprisingly, never the real question whether parenteral nutrition per se is beneficial in 
critically ill children has been asked.  
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The aim of this PhD project is to gain understanding in the clinical effect and the current practice of 
supplementing parenteral nutrition when enteral nutrition is insufficient in pediatric patients during critical 
illness. 
 
 
In the first part (chapter 3,4) we study the current nutritional practice in pediatric critical ill patients. Firstly we 
performed a systematic review to identify randomized controlled trials about the timing of supplemental 
parenteral nutrition. Since the current guidelines for children about nutritional support during critical illness 
are not detailed, we hypothesized in our survey that these guidelines would result in a very variable practice 
worldwide. 
 
 
In the second part (chapter 5) we examined the methodological quality of ultrasonography to diagnose 
muscle wasting in children during critical illness. 
 
 
In the third part (chapter 6,7) we planned (chapter 6), conducted and analyzed (chapter 7) an international 
randomized multicenter clinical trial with the acronym PEPaNIC, comparing early-PN to late-PN. In the 
early-PN group parenteral nutrition was initiated within two days after ICU admission unless enteral nutrition 
was sufficient or oral intake was expected to resume. In the Late-PN group, no PN was administered before 
day 8 after ICU admission. 
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3. Systematic Review: Parenteral nutrition in the 
Pediatric Intensive Care Unit 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Fivez T*, Kerklaan D*, Mesotten D, Verbruggen S, Joosten K, Van den Berghe G. Evidence for the use of 
parenteral nutrition in the pediatric intensive care unit, Clinical Nutrition (2015) 
* Equal contribution 
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Abstract 
 
Background and Aims: During hospitalization in a pediatric intensive care unit (PICU), critically ill children 
are fed artificially. Administered via the preferred enteral route, caloric targets are often not reached. Hence, 
parenteral nutrition is given to this patient population. In this review we analyzed the available evidence 
from randomized controlled trials (RCTs) that supports the use of parenteral nutrition in children during 
critical illness.  
Methods: A search strategy in Ovid MEDLINE and Ovid EMBASE was created and trial registries were 
screened to identify the relevant RCTs. Studies were included if they were randomized controlled trials, 
involved pediatric patients admitted to PICU, and compared different dosing/compositions of parenteral 
nutrition.  Descriptive studies and reviews were excluded. 
Results: Of the 584 articles identified by the search strategy, only 114 articles were retained after title 
screening. Further abstract and full text screening identified 6 small RCTs that compared two 
dosing/composition strategies of parenteral nutrition.  These trials reported differences in surrogate 
endpoints without an effect on hard clinical endpoints.  The RCTs observed improvements in these 
surrogate endpoints with the use of more calories or when parenteral glutamine or fish oil was added. 
Conclusions: The few RCTs suggest that surrogate endpoints can be affected by providing parenteral 
nutrition to critically ill children, but the studies were not statistically powered to draw meaningful clinical 
conclusions. Large RCTs with clinically relevant outcome measures are urgently needed to support the 
current nutritional guidelines that advise the use of parenteral nutrition in the PICU. 
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Introduction 
 
For critically ill children who require an admission to the Pediatric Intensive Care Unit (PICU), nutritional 
support is advised as soon as possible to prevent or reduce catabolism, with the intention to enhance 
recovery while allowing normal growth (1). The enteral route is preferred as it has been suggested that 
feeding via the gut maintains gut integrity and may reduce the risk of infection, in comparison with feeding 
via the parenteral route (1). However, when only enteral nutrition (EN) is provided during PICU-stay, caloric 
targets are often not reached.  This is explained by intestinal dysfunction as part of the critical illness, the 
administered medication that affects the gastro-intestinal tract, frequent interruptions of enteral feeding and 
the need for fluid restriction (2). Hence, a caloric deficit quickly builds up in critically ill children, the severity 
of which has been associated with poor outcomes and impaired growth (3, 4). Children are particularly 
vulnerable for accumulating a pronounced caloric deficit as their relative energy requirements are 2-3 times 
higher than those of adults. Reaching the preset caloric targets is easier when parenteral nutrition (PN) is 
administered. However, feeding children via the parenteral route has shown to increase the risk of 
metabolic disturbances such as hyperglycemia and dyslipidemia and to be associated with more 
nosocomial infections (5). Therefore, the question remains if, and when, PN should be initiated for critically 
ill children in the PICU.  
The currently available guidelines are not very specific on how energy requirements should be determined 
for critically ill children nor on how the caloric deficit should best be prevented. The European Society for 
Clinical Nutrition and Metabolism (ESPEN) and the European Society for Paediatric Gastroenterology 
Hepatology and Nutrition (ESPGHAN) guidelines state that the initiation of PN depends on the clinical 
condition and the age and size of the infant or child (6). These guidelines advocate to start PN in infants 
shortly after admission to PICU whenever EN fails, but in older children and adolescents longer periods of 
inadequate nutrition may be tolerated. The American Society for Parenteral and Enteral Nutrition 
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(A.S.P.E.N.) guidelines make no specific recommendations for the use and dosing of PN for children treated 
in the PICU (1). However, the A.S.P.E.N. guidelines state that for older children, a caloric deficit can be 
tolerated for up to one week. These different and rather non-specific recommendations have resulted in 
nutritional practices that vary widely among PICUs worldwide (7). 
Therefore, we performed an up to date review to assess all available evidence from randomized controlled 
trials (RCTs), with hard clinical as well as surrogate endpoints, that supports the use of parenteral nutrition 
in children during critical illness. 
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Methods 
 
An extensive search strategy in both Ovid MEDLINE and Ovid EMBASE was created and trial registries 
were screened to identify the relevant RCTs.  Studies were included if they were randomized controlled 
trials, involved pediatric patients admitted to PICU, and compared different dosing/compositions of 
parenteral nutrition. Parenteral nutrition was defined as intravenously administered macronutrients 
(carbohydrates, lipids, proteins) of which dosing differed between treatment groups in the included RCT’s. 
The time frame of the search strategy was from the inception of these databases up to September 7, 2015. 
Also non-English language studies were taken into account. In addition, trial registries were screened and 
reference lists of all potentially relevant studies were analyzed manually. The detailed search strategies are 
described in Appendix 1.  We included only randomized controlled trials, and any eventual post-hoc 
analyses thereof, of pediatric patients admitted to the PICU that compared different dosing/compositions of 
parenteral nutrition.  Descriptive studies and reviews were excluded. Also studies involving the adult or 
premature newborn population were excluded.  We focused on timing and dosing as well as composition of 
parenteral macronutrients and did not address other nutritional aspects in the PICU.  The initial focus was 
on studies with hard clinical outcome measures (such as infections, length of PICU stay in PICU, or 
mortality). However, a systematic review from 2009 revealed that one study used a clinical outcome 
measure. Therefore, we also included studies with surrogate endpoints (such as nitrogen balance or 
markers of inflammation). The quality assessment of the individual studies was based on the Jadad score 
(8) and the Black and Downs score (9). 
Two authors (TF, DK) independently screened the search results. Two selection criteria were premised for 
title and abstract screening. First, the study population had to consist of term neonates, infants, children or 
adolescents treated in the PICU. Secondly, the studies needed to investigate parenteral nutritional support 
during hospitalization in PICU. For the full text screening, these criteria were further narrowed to (a) an age 
range of 37 weeks gestational age to 18 years of age and (b) to randomized controlled trials in which dosing 
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and/or timing of mixed-bag PN or one of its components (amino acids, lipids, glucose) differed between the 
randomly allocated groups. Hence, studies comparing EN strategies were excluded. TF and DK 
independently determined eligibility. In case of discrepancy, SV and KJ decided on inclusion by consensus. 
Figure 1: Flowchart of screening process 
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Results 
 
After title screening, 114 articles were retained (Fig 1). The main reasons for these initial exclusions were 
(a) non-PN related aspects of nutrition, such as dosing of EN and (b) non-randomized controlled trials. After 
further screening of the abstracts and an additional manual search, 8 articles were retained (10-17). Of 
these, full text reading resulted in exclusion of another 2 articles, one that was related to EN instead of PN 
and one was not a RCT (15, 16). Table 1 gives an overview of the 6 trials, of which 1 was a post-hoc 
analysis of one of 5 RCTs (11), that were identified as relevant for this review.  As the retained studies used 
different interventions and outcome measures they could not be analyzed in a formal meta-analysis.  
The RCT by Larsen et al., as well as the post hoc analysis of this RCT, investigated 32 infants undergoing 
elective open-heart surgery with cardiopulmonary bypass and compared the effect of the pre- and post-
operative administration of two types of parenteral lipid formulas, namely Intralipid® (LCT soybean oil) in the 
control group and Lipoplus® (50% MCT, 40% LCT, 10% Fish oil) in the intervention group (11, 17). In the 
primary trial (17), the authors report significantly lower plasma concentrations of TNF-alpha and IL-6 
(primary outcome measures) on the first postoperative day in the treatment group receiving Lipoplus®.  On 
day 7, the plasma TNF-alpha and IL-6 concentrations were no longer different. Also duration of stay in 
PICU/hospital, incidence of sepsis, inotrope scores or ventilator days (secondary outcome measures) were 
similar in both groups. The post hoc analysis (11) also reported lower levels of other inflammation 
biomarkers (procalcitonin, leukotriene B4, lymphocytes) in the Lipoplus® group. 
Two RCTs by Chaloupecky et al. were studies of 29 and 37 infants, respectively, undergoing cardiac 
surgery, in which the impact on proteolysis and plasma amino-acid profiles of early parenteral 
administration of a higher dose of amino-acids and of glucose as compared with a low dose maintenance 
glucose infusion on the first postoperative day was investigated (10, 12). Thereafter, all patients received 
enteral nutrition in equal amounts.  The authors reported less negative nitrogen balances, less proteolysis 
as suggested by urinary 3-methylhistidine excretion, and higher levels of plasma amino acids during the first 
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postoperative day in the intervention group who received more parenteral amino acids and glucose. 
Although clinical outcome measures were not explicitly described, the authors report no severe 
complications such as low cardiac output syndrome, renal failure, sepsis or mortality in any of the groups. 
Duration of intubation and inotropic support did not differ between treatment groups. 
The RCT by Jordan et al. investigated 98 children suffering from severe sepsis or admitted after major 
surgery who were identified as requiring parenteral nutrition. The study compared the impact of glutamine-
supplemented parenteral nutrition in the intervention group with standard parenteral nutrition in the control 
arm (13). The authors report that glutamine-supplemented parenteral nutrition evoked a higher plasma 
concentrations of heat shock protein 70 on day 5, whereas plasma concentrations of IL- 6 and IL-10 were 
not affected. Clinical outcome measures were not significantly different in the 2 study groups. 
The RCT by Lekmanov et al. studied 40 children with severe thermic burns and concomitant injuries and 
compared the effect of glutamine-supplemented total parenteral nutrition during at least one week in the 
intervention group to standard total parenteral nutrition in the control group (14). The authors reported no 
significant differences between the two groups for the serum levels of protein, albumin and glutamine on 
day 5 and 7 of PICU stay, but found a significantly shorter duration of mechanical ventilation in the 
intervention group (7 days versus 12 days in the control group). This result should be interpreted with 
caution, since the methods section was incomplete without information on the statistical analyses. Also 
plasma concentrations of glutamine were not significantly different between the two groups.  
Quality assessment revealed low scores for the 2 RCTs by Chaloupecky et al.; namely a Jadad score of 1 
and a Black Downs score of 9/31 for both trials, and the RCT by Lekmanov et al.; Jadad score of 2 and 
Black Downs score of 4/31. The study by Larsen et al. had a higher Jadad score of 3 but the Black and 
Downs score was only 17/31. The trial of Jordan et al. scored the highest with a Jadad score of 5 and a 
Black and Downs score of 27/31. As only 6 studies were retained, a funnel plot to assess publication bias 
could not be created. 
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Study, design Patients Comperator Intervention Outcome parameters Limitations 
Jordan I. et al. Clin Nutr. 2015  
Glutamine effects on heat shock protein 70 and 
interleukines 6 and 10: Randomized trial of 
glutamine supplementation versus standard 
parenteral nutrition in critically ill children (13). 
101 patients (1 month -14 years) with 
severe sepsis or post major surgery 
Standard PN (SPN) Standard PN plus 
Glutamine 
0.33g/kg/d (SPN + 
Gln) 
 
High Heat Shock Protein-70  
longer maintained in SPN + Gln. 
No difference in interleukin 6, 
interleukin 10 
1) Surrogate endpoints 
Larsen B. et al. JPEN J Parenteral Enteral Nutr. 
2015;39:171-179  
Pretreatment with an intravenous lipid emulsion 
increases plasma eicosapentanoic acid and 
downregulates leukotriene b4, procalcitonin, and 
lymphocyte concentrations after open heart surgery 
in infants (11). 
32 patients (neonates 40 weeks +/- 
2.2 weeks) post cardiac surgery 
Standard group 
Intralipid® 
Intervention group 
Lipoplus® (50% MCT, 
40% LCT, 10% Fish 
oil) 
Intervention group: Procalcitonin 
lower in at day 1, Leukotriene B4 
higher at day 1 and 7, but lower at 
day 10. Lymphocyte 
concentration lower 
1) Post hoc analysis 
2) Underpowered to 
draw clinical 
conclusions 
3) Intervention already  
started before surgery 
Lekmanov A. et al.Anesteziol Reanimatol 2013; 
Jan-Feb;(1):49-51 
Study of glutamine solution use efficiency in 
pediatric patients with heavy thermic burns and 
concomitant injuries in the intensive care unit (14). 
40 patients 
(2-15 years old) with thermic burns 
Standard PN 
 
Standard PN plus 
glutamine (2 ml/kg) 
Intervention group: shorter 
duration of mechanical 
ventilation. No differences in 
levels of protein, albumin or 
glutamine 
1)No statistical 
analysis description 
2) Methods 
inaccurately described 
3) Glutamine levels not 
different between 
groups 
 
Larsen B. et al. Clin Nutr. 2012 Jun;31(3):322-9 
Pre-treatment with an intravenous lipid emulsion 
containing fish oil (eicosapentaenoic and 
docosahexaenoic acid) decreases inflammatory 
markers after open-heart surgery in infants: a 
randomized, controlled trial (17). 
32 patients (neonates 40 weeks +/- 
2.2 weeks) post cardiac surgery 
Standard group 
Intralipid® 
Intervention group 
Lipoplus® (50% MCT, 
40% LCT, 10% Fish 
oil) 
Intervention group: TNF alpha 
plasma levels lower prior to and 
after surgery. Pro-inflammatory 
markers lower. 
1) Surrogate endpoints 
2) No clinical outcome 
difference 
3) Intervention already  
started before surgery 
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Table 1: Overview of 5 RCT’s and 1 post-hoc analysis identified as support of PN in critical ill children 
Chaloupecky, V. et al. J Thorac Cardio-vasc Surg 
1997;114:1053-60  
Nitrogen balance, 3-methylhistidine excretion, and 
plasma amino acid profile in infants after cardiac 
operations for congenital heart defects: the effect 
of early nutritional support (10). 
37 patients (2 months -1 year) post 
cardiac surgery 
Standard group 
Glucose 10%                                                   
25 kcal/kg                                                 
Intervention only on 
day 1 postoperatively 
afterwards EN (no PN) 
PN group 
Glucose 10-20% and 
amino acid 0.8 g/kg/d 
33 kcal/kg 
Intervention only on 
day 1 postoperatively 
afterwards EN (no PN) 
PN group: Nitrogen balance less 
negative on day 1. 
Standard group:  decrease in 
plasma levels of branched amino 
acids (valine, leucine, isoleucine), 
alanine, glycine  and proline on 
day 2 
1) Surrogate endpoints 
2) Short intervention 
time 
Chaloupecky, V. et al. Cor et Vasa 1994;36:26-34 
The effect of early parenteral nutrition on amino 
acid and protein metabolism in infants following 
congenital heart disease surgery in extracorporeal 
circulation (12). 
29 patients  
(6.5 months +/- 3 months) post 
cardiac surgery 
Standard group 
Glucose 10%  
Intervention only on 
day 1 postoperatively 
afterwards EN (no PN) 
PN group Glucose 
20% and amino acid 
0.8 g/kg/d Intervention 
only on day 1 
postoperatively 
afterwards EN (no PN) 
PN group: Nitrogen balance less 
negative on day 1. 
Standard group:  decrease in 
plasma levels of branched amino 
acids (valine, leucine, isoleucine), 
glutamine, arginine  and proline 
on day 2 
1) Surrogate endpoints 
2) Short intervention 
time 
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Discussion 
 
This systematic review could identify only 6 small RCTs that investigated the impact of a different dose 
or composition of PN in critically ill infants or children treated in the PICU.  Of these 6 studies, 4 
investigated infants after cardiac surgery and two included children with sepsis or after other major 
surgery, or burns respectively. The focus of these few studies was on intermediate or surrogate 
endpoints, such as nitrogen balances and inflammation markers, which appeared to be beneficially 
affected by providing more or altered parenteral nutrition early during critical illness. As the studies were 
small, all were statistically underpowered to detect a clinically relevant effect on patient-centered 
endpoints. Only the RCT by Lekmanov et al. reported a significant reduction of the duration of 
mechanical ventilation in children receiving glutamine-supplemented parenteral nutrition. However, with 
limited information on the used methodology which lacked a statistical analysis plan, the accuracy of 
these results cannot be determined.  Hence, strong clinical conclusions cannot be drawn from these 
studies. As a result, no recommendations can be made regarding the optimal timing for initiation and 
composition of parenteral nutrition for use in critically ill infants and children.   
The lack of large RCTs on the use of parenteral nutrition in critically ill infants and children is striking. 
However, this is an observation that is not limited to the nutritional field. Indeed, there are only 7 
randomized controlled trials of PICU patients that have addressed a clinical question with a large 
enough sample size to be able to detect a difference in patient-centered, hard clinical outcomes (18-25), 
of which 3 are related to metabolic aspects (19, 20, 23). This overall lack of large RCTs in PICU patients 
suggests difficulties in recruiting large numbers of patients, due to the fact that the number of PICU 
patients and the size of the PICUs worldwide are smaller than for adult intensive care.  
All the trials retained by the search strategy of this systematic review focused on surrogate endpoints, 
such as nitrogen balances and inflammation markers. This may hold some risks. Surrogate nutritional 
outcome measures are often used to describe mechanistic effects of an intervention. However, there is 
often a weak relationship, if any, between these surrogate endpoints and the important patient-centered 
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clinically relevant outcomes. Sometimes surrogate endpoints can be misleading as they may 
inadvertently suggest a benefit whereas the clinical outcomes indicate harm. For example, a large well-
designed RCT of critically ill adults found that the administration of growth hormone, with the intention to 
improve anabolism and outcome, improved nitrogen balances but increased mortality (26). Also another 
large trial showed that early PN in adult ICU patients reduced markers of inflammation while it increased 
infections, weakness and organ failure and slowed down recovery (27). Surrogate outcome measures 
are also the main focus of limited pediatric studies on glutamine-supplemented parenteral nutrition, that 
failed to show any advantage in critically ill children, just as enteral supplementation of glutamine (28). 
Glutamine supplementation is no longer supported in adult critical care, based on the results of recent 
large high-quality RCTs that showed either no effect on morbidity or revealed and increased late 
mortality with glutamine supplementation (29-31).  
In contrast to the PICU, there appears to be a greater consensus in the neonatal ICU, in favor of early 
parenteral supplementation. However, again the evidence generated by large RCTs with hard clinical 
endpoints is quite limited. In a Cochrane review, Trivedi et al (32) included 7 RCTs comparing the effect 
of intravenous early amino acid administration (within 24 hours after admission) with late initiation (>24 
hours) in 394 low birth weight neonates on short-term in-hospital outcomes including mortality, early and 
late growth or neurodevelopment. There were no differences in length and occipitofrontal circumference, 
however nitrogen balance improved with early administration of amino acids. The impact on other 
outcomes was not reported. Only with early initiation of parenteral lipids, an improved neonatal growth 
has been suggested by two RCTs of very-low-birth-weight infants (33, 34).  
In contrast with the pediatric critically ill patient population, recent large and high quality trials have 
provided more evidence to support nutritional recommendations for adult critically ill patients (27, 35-
37). The EPaNIC (the impact of early parenteral nutrition completing enteral nutrition in adult critically ill 
patients trial) compared early parenteral supplementation of insufficient enteral feeding with tolerating 
the caloric deficit that accumulates when EN only is given in 4640 adult ICU patients (27). This study 
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found that not using PN during the first week in ICU resulted in fewer new infections, less ICU acquired 
weakness with earlier weaning from mechanical ventilation (38), less liver dysfunction(39) and reduced 
need for renal replacement therapy, together resulting in an earlier live discharge from the ICU and from 
the hospital (27). The SPN (the impact of supplemental parenteral nutrition on infection rate, duration of 
mechanical ventilation and rehabilitation in ICU patients) trial compared the initiation of PN on day 4, 
when adult patients were not yet receiving 60% of their caloric needs, with tolerating a nutritional deficit 
with EN until day 8 (37). The SPN trial showed no differences in the clinically relevant outcomes. The 
early Parenteral Nutrition trial investigated whether PN should be started very early in critically ill 
patients when there was a short-term relative contra-indication to EN and apart from a shorter duration 
of mechanical ventilation (which was a tertiary outcome measure) there were no other clinical benefits 
(36). The evidence generated from these trials has resulted in a change in clinical practice of adult 
intensive care, with a tendency to delay initiation of PN and to accept the macronutrient deficits for up to 
one week in ICU (40).  
While the evidence from high quality RCTs no longer supports the early use of PN for critically ill adult 
patients, and while the literature may suggest the opposite for preterm newborns, there is currently no 
evidence to support any of the current PN practices for critically ill patients from term neonates to 
adolescents.  Although several observational studies of large cohorts of critically children have shown a 
relation between the adequacy of feeding and of protein intake during the first 10 days of admission and 
lower risk of death (4, 41), the adult literature calls for caution in assuming that this association is 
causal.  Hence, whether and for how long the substantial macronutrient deficit that accumulates in 
critically ill infants and children on enteral feeding only can be tolerated remains an open question. 
Further research is therefore necessary to address this question and to determine the role of PN in the 
PICU population.  In order to answer this important question, the study should be large enough to have 
enough statistical power to detect relevant differences in hard clinical endpoints. The results of the 
currently ongoing multicenter randomized controlled PEPaNIC trial (Clinical Trials.gov NCT 01536275), 
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will hopefully elucidate some of the controversial topics. The PEPaNIC trial is a study of 1440 critically ill 
infants and children, and compares the effects of early PN with no PN for up to one week in PICU on 
several patient-centered clinical endpoints such as new infections and the duration of PICU 
dependency, besides safety endpoints including mortality (42).  
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Abstract 
 
Objective 
To assess current nutritional practices in critically ill children worldwide.  
Design 
A two-part online, international survey. The first part, the survey, was composed of 59 questions 
regarding nutritional strategies and protocols (July-November 2013). The second part surveyed the 
point-prevalence of nutritional data of patients present in a subgroup of the responding PICUs (May-
September 2014).  
Setting 
Members of the World Federation of Pediatric Intensive and Critical Care Societies were asked to 
complete the survey. 
Subjects 
Pediatric critical care providers. 
Interventions 
Survey. 
Measurements and Main Results 
We analyzed 189 responses from 156 PICUs in 52 countries (survey). We received nutritional data on 
295 patients from 41 of these 156 responding PICUs in 27 countries (point-prevalence). According to 
the survey, nutritional protocols and support teams were available in 52% and 57% of the PICUs, 
respectively. Various equations were in use to estimate energy requirements; only in 14% of PICUs 
indirect calorimetry was used. Nutritional targets for macronutrients, corrected for age/weight, varied 
widely. Enteral nutrition (EN) would be started early (within 24 hours of admission) in 60% of PICUs; 
preferably by the gastric route (88%). In patients intolerant to EN, parenteral nutrition (PN) would be 
started within 48 hours in 55% of PICUs. Overall, in 72% of PICUs supplemental PN would be used if 
EN failed to meet at least 50% of energy delivery goal. 
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Several differences between the intended (survey) and the actual (point prevalence) nutritional practices 
were found in the responding PICUs, predominantly overestimating the ability to adequately feed 
patients. 
Conclusion 
Nutritional practices vary widely between PICUs worldwide. There are significant differences in 
macronutrient goals, estimating energy requirements, timing of nutrient delivery, and threshold for 
supplemental PN. Uniform consensus-based nutrition practices, preferably guided by evidence, are 
desirable in the PICU. 
 
Keywords (max 6): Pediatric; intensive care units; nutritional support; parenteral nutrition; enteral 
nutrition; questionnaires 
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Introduction 
 
Nutritional support affects recovery and outcome in critically ill children [1-3]. Although undernutrition 
has been the primary focus, overfeeding in Pediatric Intensive Care Units (PICUs) is also associated 
with increased morbidity [4, 5]. Despite its clinical relevance, there is a scarcity of high-level evidence on 
various aspects of nutritional support in critically ill children [6]. With grade C as the maximum level of 
evidence, available guidelines for nutrition support in critically ill children are based on insufficient data 
for evidence-based recommendations.  
Consensus-based guidelines provided by expert committees (American Society for Parenteral and 
Enteral Nutrition (A.S.P.E.N.), European Society for Clinical Nutrition and Metabolism (ESPEN) and the 
European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)) are based on 
scant evidence, and are largely driven by expert opinion and extrapolations from studies in adults or 
non-critically ill children [7, 8]. Low-grade or inconclusive evidence-based protocols represents a barrier 
to implementation with differences most prominent in areas with the weakest evidence [9, 10]. This 
allows wide variations in nutritional practices for patients in European PICUs as shown in previous 
studies [11, 12]. The variability in timing, amount and composition of nutrition would inevitably result in 
underfeeding and/or overfeeding, which could potentially impact the clinical outcome of critically ill 
children and overall health care expenses [13]. While evidence on many aspects of nutrition is lacking, 
there appears to be consensus on the benefits of early enteral nutrition (EN) and need to prevent further 
nutritional deterioration in this population. 
The purpose of our study was to assess the current nutritional practice in PICUs across the world. We 
hypothesized that the limited guidelines available have not been universally implemented, and that 
current practice is heterogeneous and mostly physician based. Since the guidelines at least agree on 
the importance of EN [7, 14, 15], we expected no significant differences in this practice between PICUs. 
Other factors, such as assessment of energy requirements or use of parenteral nutrition (PN), are more 
likely to vary between countries and hospitals given the weak recommendations.  
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To quantify the variations in clinical practice, we distributed a two-part online survey to PICUs across the 
world. The first part of the survey was composed of questions on various aspects of local nutritional 
practice. The second part was a point-prevalence survey on nutritional data collected in all patients 
present in the unit on a single day in a subgroup of the responding PICUs. Answers were analyzed, 
correlated with PICU characteristics and differences between the intended (survey) and the actual (point 
prevalence) nutritional practices were determined. 
 
Material and Methods 
 
The local Institutional Review Board of the Erasmus MC in Rotterdam waived the need for consent. The 
participation in this survey was voluntary and no patient identifiers were collected. 
The cross-sectional survey was conducted between July and November 2013. The online questionnaire 
was composed of 59 questions regarding local nutritional protocols and strategies, and provided in 
English, French, Spanish and Chinese. The second part, the point-prevalence, conducted between May 
and September 2014, involved data collection on nutritional practices and intake for the preceding 24 
hours. In a subgroup of centers that agreed to participate in this portion of the study, respondents were 
asked to include data for all patients present in their PICU; no selection criteria were applied. Both 
questionnaires are available as an online digital supplement.  
Testing of clarity, relevance and clinical sensibility of the English questionnaire was performed by 
independent clinicians in three centers (Sophia Children’s Hospital-Erasmus MC, Rotterdam, the 
Netherlands; University Hospital of Leuven, Belgium; and the Boston Children’s Hospital, U.S.A.). Data 
from this test were not included in the final analysis and survey results. Afterwards, the questions were 
translated to French, Spanish and Chinese by native speakers.  
An invitation to the survey was electronically distributed to members of the World Federation of Pediatric 
Intensive and Critical Care Societies (WFPICCS) by their mailing list and to specific members of the 
European Society of Paediatric and Neonatal Intensive Care (ESPNIC) and Society of Critical Care 
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Medicine (SCCM) involved in nutritional management, and through the newsletter of both the ESPNIC 
and WFPICCS and the WFPICCS homepage and LinkedIn group. A reminder was sent 2 months after 
the first invitation. Due to incomplete data registration, the exact number of PICUs represented by the 
WFPICCS database is unknown. Respondents that provided their contact information in the survey, 
were approached to participate in the point-prevalence.  
If more than one questionnaire was returned from a single PICU, the answers were weighted by the 
inverse of the number of completed questionnaires per center, in order to process conflicting statements 
within a single institution without disrupting the weight of the answers per PICU. Countries were 
classified by income according to The World Bank income groups [16]. Individual questions were 
stratified by continent, income of country, number of PICU beds, admissions per year and percentage of 
ventilated patients.  
Statistical analysis was performed using IBM SPSS statistics 21 for Windows (IBM, Chicago IL, USA). 
Descriptive statistics were used to compare differences in respondent characteristics and survey 
responses. Nutritional data obtained in the point-prevalence, were compared to the survey results for 
each participating center. Logistic regression, ordinal or multinomial, depending on the type of outcome, 
was used to identify the relation between the answers provided and the characteristics of the different 
PICUs. To correct for cluster effects due to multiple returned questionnaires per PICU, generalized 
estimating equations were used in conjunction with robust standard error estimates (Huber sandwich 
estimator). All statistical tests were two-sided and statistical significance was defined as a P-value < 
0.05. 
This trial was registered in the Dutch Trial Register (NTR) at number 4093 (www.trialregister.nl). 
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Results 
 
Response 
After distribution of the first part of the survey a total of 251 questionnaires were received. Fifty-two 
questionnaires were removed because of missing essential data, defined as nutritional data (so only 
information on PICU characteristics available) and/or data essential for distinguishing PICUs from each 
other without possibility for clarification. Of the remaining 199 questionnaires, 10 were duplicate replies 
by the same respondent and therefore deleted. 189 questionnaires were analyzed, representing 156 
PICUs in 52 countries and 6 continents as shown in Figure 1.  
For the point-prevalence we collected nutritional data on 295 patients in total, from 41 of the responding 
PICUs (26%) from 27 countries on 6 continents with a median input of 5 patients (IQR 2-9) per PICU. 
Characteristics of responding PICUs for the point-prevalence were similar compared to the overall 
survey respondents (Table 1). 
PICU and patient demographics 
The responding PICUs in the first part of the survey represented approximately 90,000 admissions per 
year. Fifty-two percent of PICUs were located in North-America and Europe. Fourteen percent of PICUs 
were situated in low or lower middle income countries and 86% of PICUs were multidisciplinary. All 
PICU demographics are shown in Table 1. 
Of the 295 patients included in the point-prevalence, 60% was male and 58% younger than 1 year. 
Median length of stay (LOS) at moment of data collection was 6 days (IQR 2-15), with a LOS greater 
than 7 days in 40% of the patients. Median weight was 7 kg (IQR 4-16) and 46% of the children were 
mechanically ventilated.  
Nutritional support 
According to the first part of the survey, a nutritional protocol was present in 52% of PICUs; protocol 
characteristics are shown in Table 2.  A Nutrition Support Team (NST) was available in 57% of the 
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PICUs and 51% of the teams visited the ICU daily. The composition of an NST differed; it consisted 
mostly of dieticians (88%) and pediatric intensivists (51%).  
In the point prevalence part of the study, median caloric intake did not differ in children fed by EN 
exclusively (n=129) between the following four groups (p=0.18); 1. PICUs with an NST (76 kcal/kg/day), 
2. PICUs with a nutritional protocol (76 kcal/kg/day), 3. PICUs with both an NST and nutritional protocol 
(64 kcal/kg/day,) 4. PICUs without an NST and protocol (58 kcal/kg/day).There was also no difference in 
the proportion of children receiving EN in PICUs with and without an NST and/or protocol. 
Nutritional requirements 
To predict energy expenditure (EE) different equations were used according to the first part of the 
survey, mainly those published by Schofield (25%) and the WHO (25%), but also the Harris-Benedict 
equation (17%) [17-19]. Seventy percent used correction factors, as fever (41% of PICUs), diagnosis 
(54%) and growth (23%) to calculate energy needs. Twenty-four percent of respondents did not know 
which equation was used to calculate EE in their unit. Indirect calorimetry (IC) to measure EE was used 
in 14% of the PICUs. The first IC measurement was performed if expected stay was longer than 4 days 
(31% of PICUs), as soon as ventilator settings were appropriate (18%), in case of weight loss (15%) or 
patient dependent (11%: obese patients, high risk of malnutrition).  
Age based-protein targets recommended by the A.S.P.E.N. and ESPEN/ESPGHAN guidelines (ranging 
from 0.9 to 3 g protein/kg/day) were followed in 31% and 36% of PICUs, respectively [7, 8]. Lipid targets 
ranged from < 1.5 to > 3.5 g/kg/day; where the range of 1.5 to 2.5 g/kg/day was predominantly used 
(41%). Sixteen percent and 7.9% of the respondents did not know what their protein and lipid targets 
were, respectively. 
In the point-prevalence, median caloric intake was 66 kcal/kg/day (IQR 49-96) for children on EN 
exclusively (n=129); intake per kg of weight decreased significantly with age as expected (p<0.001, Fig. 
2). In 31% of the children the caloric intake was lower than basal metabolic rate calculated by the 
weight-based Schofield equation; for the WHO equation this was 27%. Median protein intake was 1.8 
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g/kg/day (IQR 1.2-2.6); only 34% of the children met the intended target protein intake of their PICU as 
mentioned in the survey.  
Timing and route of nutrition 
In the first part of the survey, an early start (within 24 hours after admission) of EN was mentioned for 
60% of PICUs; in 31% EN would even be started within 12 hours (Fig. 3). Fifty-nine percent of the 
respondents had the perception that they were able to feed patients exclusively by enteral route within 3 
days post-admission. The gastric route was preferred for EN in ventilated (67% of PICUs) and non-
ventilated patients (88%). Pro-kinetics were prescribed when a patient was not tolerating feeds in 70% 
of PICUs. EN was stopped or decreased due to the following reasons: high gastric residuals (73% of 
PICUs), abdominal distension/pain (85%), diarrhea (32%), vomiting (75%), reduced/altered bowel 
sounds (23%), hemodynamic instability (62%) or use of muscle relaxants (12%). 
Early PN would be started within 48 hours after admission in 55% of PICUs, while in 3.5% of PICUs 
there would be trials of EN for of at least 7 days before starting PN (Fig. 3). When EN was insufficient, 
respondents from 18% of the PICUs would always supplement PN, whereas in 7.5% supplemental PN 
would never be utilized. Seventy-two percent supplemented PN if EN failed to meet 50% of target 
calories; 24% if EN failed to meet 80%. PN was stopped in 64% of PICUs when EN covered > 80% of 
the nutritional targets. 
At the moment of our point-prevalence 73% of the children received EN (n=216), predominantly by 
gastric tube (70%). There was no difference in caloric intake (p=0.82) or in pro-kinetics use (p=0.47) 
between children fed by gastric or post-pyloric route. Forty-two percent of children with LOS < 24 hours 
(n=43) were already receiving EN and in children with LOS of 2 days or more (n= 253), EN was 
provided in 78%. Twenty-one percent of all children received PN in some form and 10% received a 
combination of EN and PN; both groups at a median LOS of 6.5 days. The point-prevalence showed 
that the ability to administer exclusive EN was overestimated; 40% of children (n=74) present during the 
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point-prevalence achieved exclusive EN later than perceived by the respondents from the first part of 
the survey.  
Glucose and glycemic control 
In the first part of the survey, target intake of glucose during the first 12-24 hours of admission varied 
between < 2 to > 6 mg/kg/min for different weight ranges (Fig. 4). In 62% of the PICUs a protocol for 
some form of glycemic control was available. Target blood glucoses were defined as < 10 mmol/L (<180 
mg/dL), in 54%, and < 8 mmol/L (< 144 mg/dL) in 23%. Tight glucose control (2.8-4.4 mmol/L or 50-80 
mg/dL < 1 year or 3.9-5.5 mmol/L or 70-100 mg/dL 1-16 years) as reported by Vlasselaers et al [20] was 
practiced in 10% of PICUs.  
At the time of the point-prevalence, 20 children, median weight 8.1 kg, received exclusive  glucose 
infusion while being admitted < 24 hours; median glucose intake was 1.7 mg/kg/min (IQR 0.3-2.3). 
Seventy-five percent received less glucose than their target glucose intake (Fig. 4).   
Insulin was administered in 32 children (11%); 24 children on insulin were admitted to a PICU with a 
glucose target < 10 mmol/L (<180 mg/dL), five to a PICU that practiced tight glucose control as reported 
by Vlasselaers et al [20]. 
Administration of parenteral lipids and protein 
According to the first part of the survey, lipids were supplied in different compositions (Table 3). In 44% 
of PICUs a step-up protocol was used that would start at 50% of the maximal dose. Lipid intake was 
decreased when triglycerides were 3.5-5.5 mmol/L or 310-487 mg/dL (in 69%) and stopped when 
triglycerides exceeded 5 mmol/L or 442 mg/dL (in 70%). In case of sepsis, lipid administration was 
decreased or stopped in 50% of PICUs. Reasons provided to decrease or stop the intake of protein 
were kidney failure (65%) and urea levels >15 mmol/L or 42 mg/dL (75%). 
Geographic and socioeconomic differences 
An NST was more often available in PICUs situated in North America (p=0.014), South America 
(p=0.005) and Oceania (p=0.013) than in Europe, and in PICUs with more admissions per year 
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(p=0.029). A higher percentage of nutritional protocols (p=0.006) and support teams (p<0.001) were 
available in high-income countries than low-middle ones. As expected, protein targets in North American 
PICUs were more often based on A.S.P.E.N. (p=0.011) and less frequently on ESPEN/ESPGHAN 
guidelines (p<0.001) than protein targets in Europe. EN was started earlier in PICUs in high-income 
countries (mean 6-24 hours; 81% within 24 hours) than in lower-middle-income countries (mean 13-48 
hours; 74% within 24 hours, p=0.012). PN was started later in PICUs in North America (median 2-4 
days, p=0.02) and Asia (median 2-4 days, p=0.06) than in PICUs in Europe (median < 48 hours) in a 
child intolerable to enteral feeds. An overview of the adjusted Odds Ratios per continent is provided in 
Supplemental Digital Content - Table 1.  
 
Discussion 
 
Nutritional practices vary greatly between PICUs worldwide. Several aspects of nutritional support differ 
significantly; such as macronutrient goals, preferred route and timing, estimation of energy 
requirements, and the threshold for supplemental PN use. These differences were apparent between 
PICUs in general, and between geographic and socioeconomic regions. Many of these areas currently 
lack evidence. This variability has been described before in PICUs in several European countries [11, 
12]. In addition, applied nutritional practice (point-prevalence) deviates from local protocols or strategies 
(survey) on multiple occasions, increasing the variation of clinical nutritional practice even more. Similar 
results were recently shown by Martinez et al, describing nutritional practices by detailed prospective 
data collection in 524 mechanically ventilated patients from 31 international PICUs [21]. They found a 
wide variation in EN recommendations not in agreement with national guidelines. 
Variation in practice was not only observed between PICUs in our current study; we also received 
conflicting statements within single institutions. We corrected for this issue, by weighting by the inverse 
of the number of completed questionnaires per center. The conflicting statements underline the 
observed variation of nutritional practices, which occurs not only between but also within individual 
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institutions. A similar discordance in practice within institutions was reported in a UK survey of glycemic 
control in PICUs [22]. 
Globally, guidelines for nutritional support have been released by nutritional organizations. The 
American (A.S.P.E.N). and European (ESPEN/ESPGHAN) societies provide specific guidelines for 
nutrition in critically ill children [7, 8]. However, they do not advise on every aspect of nutritional support. 
Agreements and differences between these guidelines and current practice, as shown by our survey, 
are summarized in Supplemental Digital Content - Table 2.  
Overall, the most striking similarity between guidelines and local implementation is the preference for 
EN as the preferred route of nutrient delivery and its early initiation in critically ill children.  
A specialized NST and feeding protocols are recommended by the A.S.P.E.N guidelines for critically ill 
children [7]. Availability of an EN protocol is associated with a lower prevalence of hospital-acquired 
infections [3], implementation of an  NST with an increase in EN use and decreased reliance on PN [23]. 
Our survey showed that a nutritional protocol and/or NST were available in approximately half the 
PICUs. In our point prevalence we found no significant difference in caloric intake and use of EN 
between patients from centers with and without protocol. However, since this was a secondary analysis, 
it cannot prove or disprove the utility of NST/protocols in general. In single centers, a stepwise EN 
algorithm has been shown to significantly improve the timing of EN initiation and the ability to reach 
nutrient delivery goals [24, 25]. The role of protocols and NSTs in optimizing clinical outcomes in the 
PICU population needs to be further examined in well-designed trials. 
The ESPEN/ESPGHAN guidelines prefer the measurement of REE to the use of equations. The 
A.S.P.E.N. guidelines recommend targeted use of indirect calorimetry (IC) in a select group of patients 
with suspected metabolic alterations or malnutrition. Both state that in the absence of IC, reasonable 
values can also be derived from formulas, e.g. Schofield, but only when applied without the use of 
universal correction factors [7, 8]. Several other sources state that nutritional therapy should be targeted 
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at REE throughout the course of illness [26, 27]. However, due to the limited availability and practice of 
IC [11], and also to inaccurate predictive equations [26-28], it is difficult to assess REE in critically ill 
children. Use of the WHO and Schofield equations, most commonly used to determine requirements, 
may lead to underfeeding and overfeeding and potentially impact morbidity and mortality [3, 4]. We 
confirmed the finding of previous studies [11] that IC to measure REE is used in a small minority of 
European (20%) and worldwide (14%) PICUs. In contrast with both guidelines, energy needs were 
calculated with use of correction factors in the majority of PICUs in absence of IC. In the point-
prevalence 2/3 of the children on exclusive EN received more calories than BMR calculated by the 
Schofield or WHO formula. 
Timing of nutrition is not widely covered by the pediatric ESPEN/ESPGHAN and A.S.P.E.N. guidelines. 
The adult guidelines from the same societies agree on the importance of early EN but contain 
contradictory recommendations regarding PN [14, 15, 29]. The importance and benefits of early EN are 
generally accepted in previous studies in adults and children [1, 30-33], and in critically ill children a 
higher intake by enteral route is associated with a lower 60-days mortality [3]. In our survey as well as in 
the point-prevalence EN was initiated early; within 24 hours after admission to the PICU. Overall, 
characteristics of EN support were quite similar between PICUs, with a preference for the gastric route. 
Also PN was started early; within 48 hours. The mentioned difference in PN initiation time between 
Europe and North America could reflect the contradictory recommendations in adult guidelines in these 
regions, which agree on the importance of early EN but not on the time at which supplemental PN 
should be started [15, 29]. The optimal timing and dose of PN is still under debate [34]. We are currently 
conducting a trial comparing early versus late supplemental PN in critically ill children who are intolerant 
of EN (ClinicalTrials.gov: NCT 01536275), which is expected to complete enrolment by the end of 2015. 
Prospective data from PICUs on patients receiving EN show that only 38-86% of energy goals were 
administered via this route [5, 35]. A variety of barriers impede EN delivery in the PICU setting [36, 37]. 
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Only 60% of the patients of the point-prevalence were actually on exclusive EN within the time frame 
mentioned in the survey. Although post-pyloric feeding might improve caloric intake [38], most patients 
evaluated in our survey and point-prevalence were fed by the gastric route with no difference in nutrient 
intake compared to children fed via the post-pyloric route (point-prevalence). The time to feed patients 
exclusively by the enteral route was short; 59% of respondents thought their PICU was able to feed their 
patients within 3 days, but this time was overestimated.  
Glucose targets in the ESPEN/ESPGHAN pediatric guidelines are supported by limited evidence; 
A.S.P.E.N does not provide recommendations on macronutrient intake due to insufficient data.  In our 
survey glucose intake targets during the first 12-24 hours tended to range between 2-6 mg/kg/min and 
decreased with increasing weight. The upper limit of glucose intake for critically ill children according to 
ESPEN/ESPGHAN (5 mg/kg/min, based on the maximal oxidation rate) was exceeded by more than 7% 
of PICUs. Our point prevalence showed that in 75% of the patients glucose intake differed from the 
glucose targets mentioned in the first part of the survey. However, we should be very careful to draw 
conclusions from that number, because only 20 children received glucose infusion exclusively during the 
first 24 hours of admission. 
Target blood glucose levels varied between tight control [20] and a target glucose < 10 mmol/L or 180 
mg/dL. This discrepancy in definitions and implementation in glucose management has been highlighted 
before [39, 40]. The discrepancy in definitions and implementation stems from the fact that uncertainties 
about risks and benefits remain [20, 41]. A recent UK trial showed no benefit [42] and another trial in 
North America is underway. 
The strength of our study is the fact that we surveyed the local nutritional strategies as well as their 
implementation in clinical practice. Furthermore, to our knowledge, it is the first study to describe the 
practices in relation to income-characteristics of countries in 6 continents.  
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However, our survey may not provide accurate representations of these geographic regions. No 
response rate can be calculated, since the exact number of PICUs represented by WFPICCS is 
unknown. The total number of PICUs in all countries joined in the WFPICCS, as identified in the 
literature, is at least 969, so our 156 PICUs represent a small proportion of all PICUs worldwide. Our 
point prevalence data represent a small fraction of children in the PICUs per center as well as in the 
cohort invited to participate. The smaller number of PICUs in the point-prevalence study may have 
caused an aggravation of the selection bias, since it is possible that we mainly received point-
prevalence data from PICUs with a strict protocol adherence. Hence, observations may not depict actual 
practices in these centers. However, characteristics of responding PICUs for the point-prevalence were 
similar compared to the overall survey respondents (table 1). Furthermore, many physicians have 
limited knowledge of nutritional practices in their centers. Our study may also be limited by the 
possibility that non-respondents of this survey were less interested in nutritional practices leading to a 
selection-bias and possible distorted reflection. On the other hand, this selection-bias may strengthen 
our conclusion, if even in the nutrition-minded respondents, adherence to available guidelines is limited. 
Finally, the heterogeneity of the PICU population may have caused some difficulties; many of the 
questions required an unambiguous answer, so only most applicable answers were provided. And, as 
feeding practices differ between populations, answers from combined PICUs (with neonates or adults; 
respectively 20 and 6% of the responding PICUs in this study) may falsely increase the perception of 
variability. 
Nevertheless, our survey clearly demonstrates the international variation in nutritional practice in 
critically ill children and the differences due to the limited available guidelines; especially on 
macronutrient administration and calculation of energy targets. Evidence-based guidelines are needed, 
but are challenging to develop due to a heterogeneous PICU population. Guidelines can be either very 
specific in respect to disease and settings, leading to wide variation of practice, or be generally 
applicable with risk of being unfocused and therefore irrelevant in specific situations. 
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Conclusion 
In terms of requirements, timing and route, nutritional practices among critically ill children vary greatly 
between PICUs worldwide. Even the limited available guidelines are not consistently followed and high-
level evidence is urgently needed.  
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Figure legends 
 
Figure 1. Participating countries (in grey). 
 
 
 
Figure 2. Caloric intake in different age categories in the point-prevalence; p < 0.001 when comparing 
intake in the 3 different age categories (Kruskal-Wallis test) 
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Figure 3. Early initiation of enteral and parenteral nutrition. 
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Figure 4. Varying target glucose intake in the first 24 hours of admission. 
 
< 
10
 k
g
10
-3
0 
kg
> 
30
 k
g
0
10
20
30
40
50
< 2 mg/kg/min
2-4 mg/kg/min
4-6 mg/kg/min
> 6 mg/kg/min
Weight
%
 o
f 
P
IC
U
s
 
 
 
 
  
  
75 
 
Tables 
 
Table 1. PICU characteristics of the first (n=156) and point-prevalence part (n=42) of the survey 
Characteristic Number of PICUs (%) 
 Part 1: survey 
N=156 
Part 2: point-
prevalence  
N=42 
Continent 
Asia 
Africa 
Europe  
North-America  
Oceania 
South-America 
 
37 (24%) 
5 (3.2%) 
48 (31%) 
33 (21%) 
9 (5.8%) 
24 (15%) 
 
9 (21%) 
2 (4.8%) 
17 (41%) 
3 (7.1%) 
2 (4.8%) 
9 (21%) 
Income category (country) 
Low 
Lower middle 
Upper middle 
High 
 
1 (0.6%) 
20 (13%) 
49 (31%) 
86 (55%) 
 
0 (0.0%) 
2 (4.8%) 
15 (36%) 
25 (60%) 
Hospital type 
General hospital 
University hospital 
Children’s hospital 
University-children’s 
hospital 
 
31 (20%) 
51 (33%) 
20 (13%) 
48 (31%) 
 
7 (17%) 
15 (36%) 
4 (9.5%) 
14 (33%) 
Type of PICU 
Multidisciplinary/mixed 
Cardiac 
Medical 
 
135 (86%) 
6 (4.0%) 
8 (5.1%) 
 
36 (86%) 
2 (4.8%) 
2 (4.8%) 
Combination of PICU 
With adult ICU 
With Neonatal ICU 
With adult and neonatal 
ICU 
Not combined 
 
9 (5.8%) 
25 (16%) 
3 (2.0%) 
119 (76%) 
 
1 (2.4%) 
8 (19%) 
0 (0.0%) 
33 (79%) 
Size of PICU 
1-10 beds 
11-20 beds 
21-30 beds 
>30 beds 
 
76 (49%) 
51 (33%) 
23 (15%) 
6 (3.5%) 
 
20 (48%) 
14 (33%) 
7 (17%) 
1 (2.4%) 
Ventilated patients 
< 25% 
25-50% 
50-75% 
>75% 
 
22 (14%) 
55 (35%) 
49 (31%) 
30 (19%) 
 
5 (12%) 
13 (31%) 
14 (33%) 
10 (24%) 
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Table 2. Characteristics of nutritional protocols 
 
Characteristic Number of PICUs (%) 
Total 156 
Protocol available 82 (52%) 
Information in protocol 
Assessment of energy 
requirements 
Protein requirements 
Management of GRV 
Type of EN 
Amount of EN 
Composition of PN 
Amount of PN 
 
72 (89%) 
65 (81%) 
57 (71%) 
72 (89%) 
75 (94%) 
71 (88%) 
72 (89%) 
Protocol age/weight differentiated 
Not 
For EN 
For PN 
For both EN and PN 
 
6 (7.7%) 
8 (10%) 
7 (8.7%) 
59 (74%) 
GRV: gastric residual volume; EN: enteral nutrition; PN: parenteral nutrition 
 
 
Table 3. Parenteral lipid emulsions used in the PICU (more than 1 answer possible per PICU) 
 
Lipids by brand   Type Number of PICUs (%) 
Intralipid 100% soy based 101 (65%) 
SMOFlipid 30% soy, 25% olive oil, 15% fish oil, 30% MCT 44 (28%) 
Omegaven 100% fish oil 16 (10%) 
Clinoleic 80% olive oil, 20% soy 27 (18%) 
Lipoplus 10% fish oil, 40% soy, 50% MCT 5 (2.9%) 
Lipofundin 100% soy based 4 (2.2%) 
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Table 4.Overview of nutritional recommendations by A.S.P.E.N. and ESPEN/ESPGHAN and clinical 
practice. 
 
Element  A.S.P.E.N. (2009 (26)) ESPEN/ESPGHAN (2005 (27)) Our survey 
Target group Nutrition in critically ill 
children 
Parenteral nutrition in children 
Special sections for critically ill 
children 
Nutrition in critically ill 
children 
Nutrition 
assessment 
Screening to identify (risk 
of) malnutrition 
Regular measurements of 
height, weight and head 
circumference (<3 years). Skin 
fold thickness and mid arm 
circumference reflect body fat 
and protein. Biochemical 
measurements are not ideal 
Nutritional status 
administered on 
admission and during 
stay, mostly by weight 
(94%), height (50%) and 
biochemical 
measurements (60%). 
Nutritional 
protocols/support 
Support team and protocols 
may enhance delivery of 
nutrition, no effect on 
outcome. 
A NST should monitor the 
process of parenteral nutrition 
Nutritional support team 
(56.8%) and protocol 
(52.4%) available to most 
PICUs, no effect on 
caloric intake or % EN. 
Energy 
requirements 
EE assessed throughout 
course of illness. Standard 
equations often unreliable 
for estimate of EE. IC 
desirable in subgroup of 
patients, if not available, 
energy provision based on 
formulas without correction 
factors. 
Reasonable values for EE from 
prediction equations without 
stress factors. Measurement of 
REE may be useful in the 
individual patient. 
Standard equations 
commonly used; in 70% 
of PICUs in combination 
with correction factors, as 
fever (41%), diagnosis 
(54%) and growth (59%). 
IC available in 14% of 
PICUs. 
Timing of nutrition No recommendations. 
Current practice is initiation 
of EN in 48-72 hours. 
Time of initiation of PN will 
depend on individual 
circumstances and age and 
size of the child. Inadequate 
nutrition up to 7 days may be 
tolerated in older children. 
Early initiation of EN and 
PN. Supplementation of 
inadequate EN with PN in 
majority of PICUs. 
Reaching nutritional 
targets by EN remains 
challenging. 
Macronutrient 
intake 
Insufficient data at moment 
of publication to make 
evidence-based 
recommendation 
Only parenteral 
recommendations 
 
Glucose  Glucose intake in critically ill Varying glucose targets, 
mostly 2-6 mg/kg/min 
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 children limited to 5 mg/kg/min 
 
Median glucose intake 
first 24 hours 1.7 
mg/kg/min 
Protein 0-2 years: 2-3 g/kg/day 
2-13 years: 1.5-2 g/kg/day 
13-18 years: 1.5 g/kg/day 
Neonates: 1.5-3 g/kg/day 
2 months-3 years: 1.5-2 
g/kg/day 
3-18 years: 1-2 g/kg/day 
Critically ill children (3-12 years 
old): 3 g/kg/day amino acids 
Varying protein targets, 
66% not meeting target 
 
Lipids (iv) Most centers start at 1 
g/kg/day and advance over 
a period of days to 2-4 
g/kg/day with monitoring of 
TG levels 
All children: infants max. 3-4 
g/kg/day lipids, older children 
2-3 g/kg/day. In PICU: more 
frequent monitoring and 
adjustment to TG concentration 
Lipid target predominantly 
1.5-2.5 g/kg/day, adjusted 
to TG concentration 
Route of nutrition EN preferred, if tolerated. 
PN if EN in insufficient. 
Insufficient data to 
recommend appropriate 
site. Gastric route is 
preferred, post-pyloric may 
be indicated to improve 
caloric intake or in children 
at high risk of aspiration or 
intolerant to gastric feeds 
No recommendations on EN EN preferred. PN if EN is 
insufficient. 
Gastric route is preferred 
in ventilated (67%) and 
non-ventilated (88%) 
patients.  Prokinetics are 
used if a patient is not 
tolerating feeds. 
Immunonutrition Not recommended based 
on available literature at 
moment of publication 
Not recommended based on 
available literature at moment 
of publication 
No data 
PICU: pediatric intensive care unit; NST: nutritional support team; EN: enteral nutrition; PN: parenteral nutrition; 
REE: resting energy expenditure; TG: triglycerides; IC: indirect calorimetry 
 
  
  
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. An analysis of reliability and accuracy of 
muscle thickness ultrasonography in critically 
ill children and adults 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
 
Fivez T, Hendrickx A, Van Herpe T, Vlasselaers D, Desmet L, Van den Berghe G, Mesotten D. An 
analysis of reliability and accuracy of muscle thickness ultrasonography in critically ill children and 
adults.  JPEN 2015  
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Abstract: 
 
Background: Muscle wasting starts already within the first week in critically patients and is strongly 
related to poor outcome. Nevertheless, the early detection of muscle wasting is difficult. Therefore, we 
investigated the reliability and accuracy of ultrasonography to evaluate skeletal muscle wasting in 
critically ill children and adults. 
Methods: This prospective observational study enrolled 20 sedated critically ill children and 14 critically 
ill adults. Two independent investigators made 210 ultrasonographical assessments of muscle thigh 
thickness. Inter- and intra-observer reliability was calculated and cut-off levels were calculated as a 
function of muscle thickness and the expected reduction in muscle size (predefined at 20% and 30%).  
Results: Average muscle thickness was 1.67 ± SD 0.55 cm in the pediatric and 2.10 ± SD 0.85 cm in 
the adult population. The median absolute inter-observer variability was 0.07 cm [IQR 0.04 – 0.20 cm] in 
the pediatric population and 0.05 cm [IQR 0.03 – 0.09 cm] in the adult population. However, the 
absolute intra-observer accuracy had a 95% confidence interval of 0.43 cm in children and 0.22 cm in 
adults. Only a 30% decrease (0.50 cm) in muscle thickness can be detected in critically ill children.  
Conclusion: Although in the pediatric population the inter-observer variability is acceptable, the intra-
observer variability is too large with respect to the expected reduction in muscle thickness. In adults, 
ultrasonography may be a reliable tool for early detection of muscle mass wasting.  
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Introduction 
 
Critical illness results in intensive care unit-acquired weakness (ICUAW), especially in patients with a 
protracted course of disease.(1, 2) ICUAW is associated with prolonged mechanical ventilation, longer 
ICU and hospital stay and increased mortality. In the longer-term, it also impairs rehabilitation and 
recovery to fully functional autonomy, leading to poor quality of life.(1, 3, 4) 
ICUAW already starts within the first week of critical illness and is associated with this functional 
disability in the longer term. The ICUAW is the result of a combination of critical illness polyneuropathy 
and critical illness myopathy. Skeletal muscle wasting is the most typical clinical feature of ICUAW and 
stems from muscle atrophy. Therapeutic interventions are limited to early mobilization, blood glucose 
control and limiting the use of glucocorticoids and neuromuscular blocking agents.(5, 6) 
Due to the lack of therapeutic options and the important long-term consequences of ICUAW and muscle 
wasting, their early detection may be essential to steer risk stratification and preventative measures. 
Assessment of limb muscle strength by functional, volitional measurements, such as the Medical 
Research Council (MRC)-sum score and handgrip strength, appears to be the gold standard. However, 
only fully awake and cooperative patients can undergo these measurements, potentially causing a delay 
in the diagnosis of ICUAW.(7) Therefore, non-volitional muscle strength measurements, such as an 
electromyogram to detect critical illness polyneuropathy and myopathy, have been used for the early 
screening for ICUAW. However, this technique is complex, requiring expert’s interpretation.(2, 8) 
Ultrasound measurements of muscle thickness are also considered to be a non-volitional surrogate for 
muscle strength.(9) The use of ultrasonography is well integrated in daily ICU-practice. In comparison 
with computer tomography (CT) and magnetic resonance imaging (MRI), ultrasound measurements of 
muscle thickness are inexpensive and logistically less cumbersome. When using a strict imaging 
protocol, the ultrasound measurements correlate well with the CT and MRI measurements.(7, 10, 11) In 
adult critically ill patients ultrasound measurements of m. quadriceps femoris muscle thickness were 
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sensitive to detect a decrease in muscle mass in patients with a prolonged ICU-stay.(9) In a recent 
prospective, ultrasonographical evaluation of muscle wasting in critically ill patients, rectus femoris 
cross-sectional area was decreased by approximately 18% at day 10.(12) The recent paper of Tilluist et 
al. highlighted the reliability of bedside ultrasound in assessing muscle thickness in healthy 
volunteers.(13) However ICUAW is poorly characterized in children, with only case reports as 
evidence(14, 15). Neither the functional, volitional measurements of muscle strength nor the non-
volitional measurements of muscle mass, such as ultrasonography have been validated in the pediatric 
critically ill patient population. Additionally, ultrasonographical measurements of muscle mass are harder 
to standardize due to the age-dependency of muscle mass.  
In this study we therefore aimed to assess the reliability and accuracy of ultrasound measurements of 
muscle thickness during critical illness as a function of age, covering the spectrum from neonates to 
adults. The inter-observer and intra-observer variability were assessed in relation to a predefined 
decrease in muscle thickness (3).  
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Methods 
 
Study Design and Population  
This prospective observational study in a level III paediatric and adult ICU ran from October 2013 to 
June 2014 and was part of the PEPaNIC randomized controlled trial (clinicaltrials.gov number: 
NCT01536275). The study was approved by the ethics committee of the University Hospitals Leuven. 
Study patients were admitted to the ICU for various reasons such as cardiac surgery, respiratory failure 
and sepsis. Patients were only included when they were sedated, as a correct position is crucial for 
optimal scanning. Ultrasonography was performed during the first week of admission, to exclude 
patients with protracted critical illness. Patients with severe muscle disorders, severe edema, localized 
inflammation, fractures in the limb femoral lines or were on muscle relaxants were also excluded.  
 
Ultrasonography Protocol 
A linear array commercial real time ultrasound scanner (Vivid S6, GE Healthcare, Diegem, Belgium) 
was used with a 12-MHz transducer. Ultrasonographic images were collected from a transversal scan of 
the thigh with the patient in supine position, the knee extended and the muscle relaxed. The transducer 
was placed perpendicular to the long axis of the tight on three fifths of the distance from the anterior 
superior iliac spine to the superior patellar border. This position was defined beforehand with a surgical 
skin marker (Devon Surgical Skin Marker, Covidien, Mechelen, Belgium) after measuring the exact 
position with a tape measure. 
An excess of contact gel was applied to minimize image distortion. By obtaining maximal reflection of 
the bone, optimal transducer orientation was achieved and oblique scanning was minimized. A staff 
member of the department of radiology extensively trained the two independent researchers (TF, AH) to 
perform these measurements correctly and individually. All images were analyzed directly on the 
ultrasound scanner (Figure 1). Muscle thickness was defined as the distance between the superior 
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border of the muscle and the cortex of the femur. Each limb of the patient was measured two times by 
the two investigators, independently of each other. 
 
Statistical Analysis 
The coefficient of variation was calculated for duplicate measurements. In the linear regression analysis 
(Pearson correlation coefficient), results are represented with R². In the Bland-Altman test the 95% limit 
of agreement, defined as ± 1.96 Standard Deviation (SD) of the means of the  non-absolute differences 
between the paired measurements by the two observers were represented. Further the absolute 
differences, i.e. independent of the sign of the difference (both positive and negative values), was 
computed. Reliability was assessed by the intraclass correlation coefficient (ICC), using a model for 2-
way random single measures (consistency). Reliability is higher when the ICC is closer to 1.0. A p-value 
of less than 0.05 was deemed statistically significant. For the statistical analyses Matlab (R2012a The 
MathWorks Inc, Natick, MA, USA) was used.  
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Results 
 
Pediatric group 
A group of 30 patients were included in the study. The patients’ demographics are shown in table 1. In 
one child the measurement could not be done because of a central venous line in the femoral vein. The 
coefficient of variation of duplicate measurements (n=105) was 4.51% for operator 1 and 5.1% for 
operator 2. The coefficient of determination (R²) was 0.94 (p<0.0001). The average muscle thickness 
was 1.67 cm (SD: 0.55 cm) as shown in table 2. The absolute intra-observer variability, as expressed by 
the limits of agreement (± 1.96 SD, containing 95% of the samples for normally distributed samples), 
was 0.42 cm for operator 1 and 0.45 cm for operator 2. Both distributions of the non-absolute 
differences are visualized in a Bland-Altman plot in Figure 2. The median absolute inter-observer 
variability was 0.07 cm [IQR 0.032 – 0.19 cm]. The intraclass correlation coefficient between the two 
observers covering  measurements was 0.98 for single measures.  
 
Adult Group 
A group of 14 patients were included in the study. The patients demographics are shown in table 1. The 
coefficient of variation of duplicate measurements (n=86) was 1.91% for operator 1 and 1.32% operator 
2. The coefficient of determination (R²) was 0.99 (p<0.0001). The average muscle thickness was 2.10 
cm (SD: 0.85 cm) as shown in table 3. The absolute intra-observer variability, as expressed by the limits 
of agreement (± 1.96 SD, containing 95% of the samples for normally distributed samples), was 0.33cm 
for operator 1 and 0.12 cm for operator 2. Both distributions of the non-absolute differences are 
visualized in a Bland-Altman plot in Figure 3. The median absolute inter-observer variability was 0.05 
cm [IQR 0.03 – 0.09 cm]. The intraclass correlation coefficient between the two observers covering 86 
measurements was 0.99 for single measures.  
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The intra-observer 95% CI of ultrasound measurement of muscle thickness is greater than the 
predefined 20 % decrease in the average muscle thickness in our pediatric  ICU population.(3) In adult 
critically ill patients the intra-observer 95% CI of the ultrasound measurements (0.22 cm) is well below 
the predefined decrease in muscle thickness.  The accuracy in relation to the predefined decrease in 
muscle thickness is shown in table 5. The 95 % CI Bland- Altman  is the average of both  absolute intra 
observer variability as the sign of the differences is not clinical relevant.  
  
  
87 
 
Discussion 
 
Ultrasonographical measurement of muscle thickness in critically ill children can easily be done in 
sedated critically ill children and adults with low inter-observer variability. However, the moderate 
accuracy and high intra-observer variability do not allow reliably detecting a decrease in muscle 
thickness in the pediatric ICU population.  
In adult critically ill patients, the measurement of the thickness of the M. quadriceps femoris with 
ultrasound may be a good indicator of muscle wasting (16). Dubowitz and Heckmatt showed that 
ultrasonography may be useful in children in the diagnosis of neuromuscular diseases (17, 18). Little 
data is available about ICUAW and muscle wasting in pediatric critical illness. The incidence may be 
lower as their risk factors, multiple organ failure and protracted critical illness, are less common (3). 
Parenteral nutrition, supplementing insufficient enteral nutrition, as often administered to prevent muscle 
wasting in critically ill children. However in adult critical ill patients it has been recognized that 
aggressive nutritional therapy does not prevent loss of lean body mass and leads to increase of adipose 
tissue (19, 20). In critically ill children no large clinical trials have looked  at the impact of PN on patient 
centre outcome (21). One study suggest that even 6 months after a burn injury muscle protein 
deposition cannot be  improved by amino acid infusions (22). 
 Alongside the PEPaNIC randomized controlled trial, in which early versus late initiation of parenteral 
nutrition is compared in critically ill children, this study assessed the accuracy and reliability of 
ultrasound measurements of muscle thickness to detect muscle wasting. Similar measurements were 
done in critically ill adults, as more data are available in this population.  
In our pediatric population the inter-observer variability is acceptable and comparable to the 
measurements in the adult population. However, the intra-observer variability was much larger in the 
pediatric than in the adult population. When taking into account the predefined decreases of muscle 
thickness, ultrasound measurements of muscle thickness may only be just accurate and reliable enough 
in the adult population.  
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This may explain why rectus femoris muscle thickness, assessed by ultrasound, did not decrease over 
time (1, 23). There are ample reasons to explain this high intra operator variability: slight changes in 
angle, alteration in application of pressure and the presence of edema in critically ill patient. These 
pitfalls for inappropriate accuracy can only be compensated by rigorous training of the examiners and 
strict standardization of the ultrasound settings and protocol. 
Our measurements correlate with the results in the recent paper of Tillquist et al and highlight the 
accuracy of and reliability of ultrasonography in muscle thickness assessment by different 
observers.(13) The differences in reliability between the operators in this paper and the latter might be 
correlated with the study population. The majority of the study patients in this study were in ICU for a 
longer time upon muscle thickness assessment. Certainly, more studies, that cover a wide range of 
critically ill patients regarding their severity of disease but also their baseline muscle mass, need to be 
done to confirm the potential of ultrasound measurement of muscle thickness in critically ill adults.  
Instead of muscle thickness as a marker, ultrasound assessment of muscle echogenicity and the 
measurement of the cross-sectional area of the muscle may be promising alternatives (3,8). However all 
these surrogate markers of ICUAW need to be validated against patient centered functional outcomes. 
Quantification of muscle mass by CT-scan, with an inter-observer CV of 0% and an ICC of 0.998, 
appears to be much more reliable than ultrasound measurements (20). However, the risks associated 
with CT-scanning currently do not outweigh the benefit of an early detection of a rather limited (10-30%) 
loss in muscle mass without the prospect of treatments for muscle wasting. These risks of CT scanning 
encompass patient instability during transportation but also secondary malignancies in the long run(24).  
This study has several limitations though. First, no serial assessments of muscle thickness were done to 
evaluate the decrease in muscle thickness over time. Instead we tested the ultrasound measurements 
against predefined values, based on the literature, as it is impossible to predict the length of stay in the 
ICU. Second, the ultrasound measurements of muscle thickness were neither compared with muscle 
cross-sectional area or echogenicity, nor with functional markers, such as handgrip strength or MRC-
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SUM. Third, we mainly included newborns and young children, since this represents the vast majority of 
critically ill children in tertiary referral pediatric ICUs. As muscle mass increases with the bodyweight 
(25), it can be hypothesized that from a certain body weight onwards the intra-observer variability may 
become acceptable. 
In conclusion, ultrasonographical assessment of muscle thickness is hampered by high intra-observer 
variability. It may be used in critically ill adults to evaluate muscle wasting. However, its low accuracy 
and reliability, in light of the small drop in muscle thickness to be detected, make it unsuitable for the 
pediatric ICU population. Further standardization of the ultrasound protocols may improve its 
performance.  
 
 
 
 
Table 1. Baseline Demographics  
  
 
Pediatric Group (n=30) Adult Group (n=14) 
Biometrics 
Age – yr (IQR) 3 (1.3 - 6) 73 (63 - 77) 
Weight – kg (IQR) 12.2 (5.8 – 19.8) 71 (67 - 82) 
Height – cm ± SD 92.4 ± 35.6 173.5 ± 6.5 
Severity of illness 
Score ± SD 11 ± 5 (PRISM) 21 ± 8 (APACHE-II) 
Intubated – n (%) 22 (73%) 14 (100%) 
Ventilated – n (%) 29 (97%) 14 (100%) 
Vasopressors – n (%) 3 (10%) 13 (93%) 
Inotropics – n (%) 8 (27%) 3 (21%) 
Diagnostic category 
Medical – n (%) 18 (60%) 2 (14%) 
Cardia Surgery – n (%) 7 (23%) 7 (50%) 
Other Surgery – n (%) 2 (2%) 1 (7%) 
Neurlogical – n (%) 2 (2%) 3 (21%) 
Transplantation – n (%) 1 (1%) 1 (7%) 
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Table 2. Results of ultrasound measurements in Pediatric patients 
 
Parameter Average 
muscle 
thickness 
Intra-variability 
operator 1 
Intra-variability 
operator 2 
Inter-variability 
between 2 operators 
MEAN 1,67 0,11 0,11 0,11 
SD 0,55 0,11 0,11 0,10 
MEDIAN 1,61 0,07 0,06 0,07 
Q25 1,3 0,03 0,03 0,03 
Q75 1,88 0,17 0,18 0,19 
Bland-Altman     
2*1.96*SD  0,41 0,45 0,39 
 
 
 
Table 3. Results of ultrasound measurements in adult patients 
 
Parameter Average 
muscle 
thickness 
Intra-variability 
operator 1 
Intra-variability 
operator 2 
Inter-variability 
between 2 operators 
MEAN 2,10 0,05 0,03 0,08 
SD 0,85 0,08 0,03 0,09 
MEDIAN 1,79 0,03 0,03 0,05 
Q25 1,44 0,02 0,01 0,03 
Q75 2,94 0,06 0,05 0,09 
Bland-Altman     
2*1.96*SD  0,33 0,12 0,34 
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Table 4: Accuracy in relation to predefined decreases in muscle thickness 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Screenshot of a muscle thickness measurement by ultrasound. Transversal scan of the thigh 
with the patient in the supine position, with the knee extended and the muscle relaxed. Muscle 
thickness is measured by the distance between the superior border of the muscle and the cortex of the 
femur. 
 
 
 
 
 
 
 
 
                          
Subgroup 
20% decrease 30% decrease 
95% CI 
Bland-Altman 
Paediatric 0.34 cm 0.50 cm 0.39 cm 
Adult 0.42 cm 0.63 cm 0.22 cm 
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Figure 2. Bland-Altman plot of the muscle thickness measurements in pediatric critically ill patients. 
Operator 1 (circles); operator 2 (stars). 
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Figure 3. Bland-Altman plot of the muscle thickness measurements in adult critically ill patients. 
Operator 1 (circles); operator 2 (stars). 
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ABSTRACT 
 
Background 
The state-of-the-art nutrition used for critically ill children is based essentially on expert opinion and 
extrapolations from adult studies or on studies in non-critically ill children. In critically ill adults, 
withholding parenteral nutrition (PN) during the first week in ICU improved outcome, as compared with 
early supplementation of insufficient enteral nutrition (EN) with PN. We hypothesized that withholding 
PN in children early during critical illness reduces the incidence of new infections and accelerates 
recovery. 
 
Methods/design 
The Pediatric Early versus Late Parenteral Nutrition in Intensive Care Unit (PEPaNIC) study is an 
investigator-initiated, international, multicenter, randomized controlled trial (RCT) in three tertiary referral 
pediatric intensive care units (PICUs) in 3 countries on 2 continents. This study compares early versus 
late initiation of PN when EN fails to reach preset caloric targets in critically ill children. In the early-PN 
(control, standard of care) group, PN comprising glucose, lipids and amino acids is administered within 
the first days to reach the caloric target. In the late-PN (intervention) group, PN completing EN is only 
initiated beyond PICU-day 7, when EN fails. For both study groups, an early EN protocol is applied and 
micronutrients are administered intravenously. The primary assessor-blinded outcome measures are the 
incidence of new infections during PICU-stay and the duration of intensive care dependency. The 
sample size (n=1440, 720 per arm) was determined in order to detect a 5% absolute reduction in PICU 
infections, with at least 80% one-tailed power (70% two tailed) and an alpha error rate of 5%. Based on 
the actual incidence of new PICU infections in the control group, the required sample size was 
confirmed at the time of an a priori planned interim-analysis focusing on the incidence of new infections 
in the control group only.  
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Discussion 
Clinical evidence in favor of early administration of PN in critically ill children is currently lacking, despite 
potential benefit but also known side effects. This large international RCT will help physicians to gain 
more insight in the clinical effects of omitting PN during the first week of critical illness in children.  
Trial registration 
ClinicalTrials.gov: NCT 01536275 on 16 February 2012.  
 
Keywords: Critical illness, children, nutrition, sepsis, lipid, protein, glucose, infection 
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Background 
 
Nutritional support for children in intensive care 
The state-of-the-art nutrition used for critically ill children is essentially based on expert opinion, small 
studies with surrogate endpoints and extrapolations from adult studies or from studies in healthy 
children outside the ICU. It is widely accepted that in healthy children, nutrition not only serves to 
maintain body tissues but also allows growth which is considered of particular importance during infancy 
and adolescence [1, 2]. In hospitalized children, especially in the young, the current European and 
American guidelines for nutrition recommend early parenteral nutrition (PN) to prevent/correct 
malnutrition and to sustain appropriate growth when enteral nutrient (EN) supply is insufficient [3, 4]. 
Observational studies suggest that about a quarter of children, most notably infants, admitted to 
pediatric intensive care units (PICUs) develop a pronounced caloric deficit [1]. The stores of energy, fat 
and protein in children are limited, leaving children to rely on muscle mass to provide necessary 
substrates for metabolism. The energy deficit observed with acute critical illness in children has been 
associated with adverse outcome [5]. Based hereon, it is current practice in PICUs to start PN in the 
acute phase of critical illness to supplement insufficient EN with the intention to avoid underfeeding [3, 
4]. However, overfeeding may also be harmful [6-9]. It is difficult to administer the correct amount of 
nutrition avoiding overfeeding as well as underfeeding.  
 
Varying nutritional guidelines and clinical practices  
It is currently advised to assess energy expenditure considered to reflect energy requirements, through 
the use of indirect calorimetry during the course of critical illness and to use this technique for 
determining individualized targets to guide nutritional therapy [10]. However, a European survey 
conducted in 2004 showed that only 17% of the PICUs use this technique [11] and the technique itself 
has not been well standardized [12, 13]. In the most critically ill, major caveats are present such as 
respiratory support with more than 40% oxygen and the use of uncuffed tubes resulting in unpredictable 
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measures. The use of standard equations to predict energy expenditure and/or requirements also 
carries the risk of overfeeding and underfeeding [14-16]. 
Experts worldwide agree that there are insufficient data to make evidence-based recommendations for 
the optimal target of caloric intake in critically ill children and for the optimal time after onset of critical 
illness by which this target should be reached. The lack of widely accepted caloric targets for critically ill 
children results in nutritional strategies that vary substantially across centers. The current European and 
American guidelines for nutrition in hospitalized children recommend PN to prevent or correct 
malnutrition and to sustain appropriate growth when EN supply is insufficient [10, 17]. Most guidelines 
advise to do this early so that the recommended daily allowances for children are reached on day 2 or 3 
after PICU admission. These recommendations are based on evidence from cohort studies without a 
control group, case series or expert opinion (Grade D level).  
The ongoing controversy on optimal amount, composition and timing of administration of PN in critically 
ill children may in fact conceal the fact that there is no hard evidence for any use of PN in critically ill 
children. Supported by the results of a Cochrane systematic review, Joffe et al. concluded that 
randomized trials investigating the role of intravenous nutritional support during the first week of critical 
illness in children should be performed and should include a control arm in which no nutritional support 
is administered or hypocaloric goals (below basal metabolic rate) for nutritional support are used [18]. 
 
Rationale of the study and study hypothesis 
A recent RCT in critically ill adults [19] showed that the early provision of PN worsened rather than 
improved outcomes as compared with withholding PN and thus tolerating a substantial caloric deficit up 
to one week in ICU. Also other studies did not show clinical benefit of early PN in adult ICU patients [20, 
21]. Hitherto, no well-designed RCT has been performed in critically ill children. The aim of the 
PEPaNIC trial (the acronym stands for Pediatric version of the effect of Early Parenteral Nutrition to 
complete insufficient enteral nutrition in ICU patients) is to investigate whether a strategy of withholding 
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PN during the first 7 days in the PICU (late PN) provides clinical benefit over the current practice of early 
PN in critically ill children. We hypothesize that withholding PN for one week in the PICU reduces new 
infections and shortens the duration of PICU-stay.  
This hypothesis is currently being tested in a multicenter superiority RCT performed in three large, 
tertiary referral PICUs (University Hospitals Leuven, Leuven, BE – Erasmus MC - Sophia Children’s 
Hospital, Rotterdam, NL – Stollery Children’s Hospital, Edmonton, CA). The centers were invited to 
participate based on a self-declared routine use of early PN in the PICU. It was anticipated that this 
routine use of early PN differs among centers. This was considered to be an asset as it contributes to 
the external validity of the PEPaNIC trial.  
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Methods/design 
 
Ethical approval 
The study protocol and (deferred) informed consent forms were approved by the institutional ethical 
review boards in Leuven BE (ML8052 Amend-ID0005), Rotterdam NL (NL38772.000.12) and Edmonton 
CA (Pro00038098). Informed consent is given in writing by the parents or the legal guardians, confirmed 
by the child when older than 7 years, after providing all information orally in plain language and in 
writing. For planned admissions, informed consent is obtained prior to surgery/procedure.  For 
unplanned admissions, informed consent is obtained within 24 hours after admission on the PICU 
(deferred informed consent as the nutritional therapy should be initiated from PICU admission onward).  
 
Patients’ eligibility – Inclusion criteria 
Upon admission to the participating PICUs, all critically ill children are screened for nutritional risk and 
eligibility for inclusion in the PEPaNIC clinical study [22]. All non-eligible patients, identified by the local 
investigators, are logged.  
Critically ill children, newborn to 17 years (inclusive or exclusive depending on the local definition of a 
pediatric patient) old, with a STRONGkids (Nutritional risk score) score of 2 points or more and who are 
likely to stay in the PICU for more than 24h, are eligible for inclusion [22].  
 
Exclusion criteria  
Patients fulfilling one or more of the following criteria are excluded: 
− STRONGkids score lower than 2 on PICU admission [22] 
− Not critically ill (e.g. anticipated oral intake within 24 hours) 
− Non-pediatric patients (Age 17 or older cfr. above)  
− Premature newborns (<37 weeks gestational age upon admission in the PICU) 
− “Do not resuscitate” code at the time of PICU admission 
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− Expected death within 12 hours 
− Readmission to PICU after already having been randomized  
− Enrollment in another intervention trial 
− Transfer from another PICU or neonatal ICU after a stay of more than 7 days 
− Ketoacidotic or hyperosmolar coma  
− Inborn metabolic diseases requiring specific diet 
− Short bowel syndrome or other conditions requiring PN for more than 7 days prior to PICU 
admission  
 
Data collection at study entry 
At baseline, data on demographic (age, gender, race/ethnicity, (pre-)admission bodyweight and height) 
and clinical characteristics of the patients are obtained. For all patients severity of illness scores are 
calculated such as the Pediatric Logistic Organ Dysfunction PELOD score and, for cardiac surgery 
patients, the Risk-Adjustment in Congenital Heart Surgery or RACHS score. The Pediatric RISk of 
Mortality (PRISM) score cannot be used for this study as the nutritional management is expected to 
affect the highest blood glucose concentration during the first 24 hours. In addition, co-morbidities prior 
to admission are noted. These comprise, among others, the presence of a genetic syndrome, 
gestational age at birth, presence/history of cancer, diabetes mellitus, kidney failure and infection upon 
admission. 
 
Randomized treatment allocation 
Randomization procedure 
Randomization to early PN or late PN in a one to one ratio, is performed centrally (KU Leuven, Belgium) 
by use of a dedicated computerized system, accessible in all centers 24-hours around the clock, 7 days 
a week. The computer algorithm allocates every consecutive, eligible patient per center to one of the 
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two treatment arms in a blinded fashion by use of permuted blocks per diagnostic stratum to create 
parallel groups. The block size is unknown to bedside physicians, nurses and members of the research 
team. Patients are stratified per study site according to age groups (<1 year and ≥ 1 year) and the 
following primary diagnostic categories on admission: 
I Medical-PICU admissions (infectious or non-infectious): (a) neurological (b) other. 
II Surgical-PICU admissions (elective or emergency) according to referral discipline (a) cardiac surgery 
(b) other. 
 
Treatment allocation and blinding  
Concealed allocation to the randomized treatment was realized by use of the computerized 
randomization system described above. It was considered not feasible to blind treating physicians and 
patients for the allocated treatment during the time window of the randomized intervention. After 
discharge to the normal ward, all treating physicians are unaware of the randomized treatment 
allocation. All outcome assessors and investigators not directly involved in the patients care, such as 
statisticians, infectious disease specialists and laboratory personnel, are fully blinded to treatment 
allocation.  
 
Common strategy for early EN in both study arms 
The initiation and increase of EN, and the use of gastroprokinetics are prescribed in the standing orders 
for EN in each center. Both groups receive micronutrients (trace elements, minerals and vitamins) 
intravenously from day 2 onwards until the amount of EN given reaches 80% of the caloric target. 
 
Randomized interventions 
Patients randomized to the early PN strategy (standard of care or control group) receive this type of 
nutrition according to current management in each of the participating centers, which were recruited 
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based on a routine use of early PN. For patients randomized to the late PN group (intervention group), 
all PN is withheld during the first week in the PICU. The international setting of the trial brings some 
variation in the control group (see study rationale and hypothesis), while the intervention group is strictly 
standardized (“no PN during the first week in PICU”).  
 
Standard of care or control group: early-PN   
In the Leuven (BE) PICU, patients randomized to the early-PN group receive a mixture of glucose 30% 
and Vaminolact® (Fresenius, Sweden) in equal amounts upon admission to PICU, comprising 150 
mg/ml glucose and 4.7 mg/ml nitrogen. For patients who require fluid restriction, total fluid intake is 50 
ml/m²/h on day 1 and 2 (the day after admission and further referred to as day 2), and 60 ml/m²/h on day 
3. Patients not requiring fluid restriction receive 100 ml/kg/day for the first 10 kg bodyweight, 50 ml/kg 
for the next 10 kg, and 20 ml/kg for the bodyweight over 20 kg, to be reached within 3 days. For all 
patients on intravenous (IV) nutrition, and within the fluid limitation described above, lipids [SMOFlipid® 
(20g/100ml) Fresenius, Sweden] are added from the second morning after admission, initially at a dose 
of 1.5 g/kg/day, increasing to a maximum of 3 g/kg/day, depending on the age. On the third morning 
after admission, pharmacy-prepared PN preparations are prescribed, unless adequate enteral nutritional 
intake is expected. PN preparations contain a mixture of glucose 50% and SMOFlipid® covering 
respectively 60-70% and 40-30% of calculated energy target and a 1.5-2.5 g/kg protein intake, 
according to age, by Vaminolact®. If the body weight is above 5 kg, Vaminolact® is replaced by Vamin 
18®. Any enterally delivered energy is taken into account twice daily to reduce the energy delivered by 
PN. When EN covers 80% of optimal calculated caloric needs, PN is stopped. When the patient starts to 
take oral nutrition, the PN and/or EN is reduced and eventually stopped. Whenever enteral or oral intake 
falls below 50% of calculated caloric needs, the PN is restarted.  
In the Rotterdam (NL) PICU, patients randomized to the “early PN” group receive a continuous glucose 
infusion upon admission to PICU (< 30 kg; 4-6 mg/kg/min, > 30 kg; 2-4 mg/kg/min). From day 2 onwards 
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the glucose intake is increased for all children on IV nutrition to 8.3 mg/kg/min (5-10 kg), 6.9 mg/kg/min 
(10-30 kg) or 4 mg/kg/min (> 30 kg). Primene® (Baxter) (5.5 – 5.7 mg/ml nitrogen) is added from day 2 
onward at 25 ml/kg/day (<10 kg) or 20 ml/kg/day (10-30 kg). From day 2 onwards, Intralipid® (Baxter) is 
added initially at a dose of 10 ml/kg/day (<10 kg) or 7.5 ml/kg/day (10-30 kg), increasing to 20 or 15 
ml/kg/day respectively. For patients who require fluid restriction, intake is adjusted accordingly. Children 
>30 kg on IV nutrition receive from day 2 onwards Olimel N5 (Baxter, 5.2 mg/ml nitrogen, 115 mg/ml 
glucose) when central lines are in place or Olimel N4 (Baxter, 4.0 mg/ml nitrogen, 75 mg/ml glucose) 
when only peripheral lines are in place. The dose is 48 ml/kg/day. Any enterally delivered energy is 
assessed twice daily and the energy delivered by PN is reduced accordingly. Energy goals for enteral 
nutrition are based on the body weight-based Schofield equation [23] (first day of admission) and on the 
Recommended Dietary Allowances (RDA, Dutch Health Council) for the subsequent length of stay 
(Dietary Reference Intake: energy, protein and digestible carbohydrates, 2001, Health Council of the 
Netherlands: The Hague). Energy goals and composition of parenteral nutrition are based on the 
ESPGHAN guidelines [4]. When EN covers 80% of calculated caloric needs, PN is stopped. When the 
patient starts with oral nutrition, PN and/or EN is reduced and eventually stopped. Whenever enteral or 
oral intake falls below 50% of calculated caloric needs, PN is restarted. 
 
In the Edmonton (CA) PICU, the patient’s energy expenditure is assessed upon admission by a 
registered dietitian when possible. Nutritional support is initiated as soon as possible, with the goal to 
match energy expenditure (measured or estimated resting energy expenditure of the child). The urgency 
of initiation of nutrition support is dependent on nutritional risk prior to admission, disease state and age. 
If indirect calorimetry cannot be done, 65% of basal metabolic rate is used (FAO-WHO) to determine 
caloric requirement. This number is adjusted daily by the dietitian based on the acute phase response 
and clinical picture of the child. If nutritional requirements cannot be met enterally, PN is added to 
achieve caloric target. On admission to PICU, patients receive a glucose infusion of approximately 3-4 
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mg/kg/minute taking into account the total fluid prescribed by medical staff. At that time EN is initiated 
when possible. On the morning of day 2, if the patient is not already on full enteral feeding, 20% IV lipids 
are initiated at 0.5 g/kg/day. On the morning of day 3, if the patient is not already on full enteral feeding, 
lipid infusion is increased to 1 g/kg/day and a solution of amino acids and concentrated glucose is 
added. The caloric goal is Basal Metabolic Rate when the patient is intubated and Total Energy 
Expenditure when the patient has been extubated.  
 
Intervention group: late-PN 
In the three centers, patients randomized to the late-PN group receive a mixture of Glucose 5% and 
NaCl 0.9% at, respectively, 60% and 40% of the total flow rate that is required to obtain optimal 
hydration, as prescribed by the attending physician, taking into account the volume of EN that is being 
delivered. No other forms of PN (lipid or protein infusions) are administered. When the amount of EN 
that is administered still covers less than 80% of the calculated targets after 1 week in the PICU, 
supplemental PN is initiated on day 8 according to the current PN protocols in each center.  
 
The medical and nursing staff of the PICU were all informed and trained  extensively during regular 
meetings before the start of the trial and were familiarized with the protocol. In order to optimize protocol 
compliance, the protocol was programmed in the patient data management system (PDMS). The use of 
this program was explained to every nurse, trainee and resident on the PICU and was always 
supervised by the senior staff.  
Adherence to the protocol in Leuven and Rotterdam was guaranteed by using a PDMS guided system 
and by careful follow-up by study nurses. In Edmonton, a paper protocol was used and adherence 
checked by an independent study nurse and physician.  
 
Criteria for stopping the study intervention 
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When in the intervention arm (late PN group), blood glucose concentration falls spontaneously (without 
exogenous insulin) below 50 mg/dl, the standard infusion of glucose 5% is switched to 10% glucose 
until blood glucose concentration is higher than 80 mg/dl and stable. Thereafter, the infusion of glucose 
10% is stopped again and switched back to glucose 5%. 
 
Blood glucose management 
In Leuven, patients in both study groups receive continuous insulin infusion to target blood glucose 
levels of 50-80 mg/dl when aged <1y and 70-100 mg/dl when aged ≥ 1 year. Blood glucose and 
potassium are monitored systematically every 1 to 4 hours on the blood gas analyzer (ABL Radiometer, 
Copenhagen, Denmark) using undiluted arterial blood samples drawn via a VAMP® system [24] and 
insulin infusion is adjusted when needed. 
In Rotterdam, patients in all age groups receive continuous insulin infusion using a step-wise nurse-
driven glucose control protocol to target blood glucose levels of 72-145 mg/dl, except for patients with 
traumatic brain injury for whom the target is set at 108-145 mg/dl [25]. Blood glucose and potassium are 
monitored systematically every 1 to 3 hours on the blood gas analyzer (ABL 625; Radiometer, 
Copenhagen, Denmark) using arterial or capillary blood samples. 
In Edmonton, patients in all age groups receive continuous insulin infusion at the discretion of the 
attending physician when blood glucose levels exceed 180 mg/dl. The attending physician sets the 
lower target range limit. 
 
Other procedures and guidelines 
Other medical treatments are not described by the study protocol. Patients are weaned from the 
ventilator and from hemodynamic support according to standardized guidelines used in each 
participating PICU. End-of-life decisions when further intensive care is considered to be futile are taken 
in consensus by senior PICU physicians and the referring specialist.  
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Handling of re-admissions to the PICU 
Patients who are readmitted to the PICU after a participation in PEPaNIC are not eligible for reinclusion. 
Patients who are readmitted to the PICU within 48 hours of discharge and who are still within the 7 days’ 
time window of the initial randomization receive the nutrition strategy they were randomly assigned to 
during the initial PICU admission. Patients readmitted more than 48 hours after PICU discharge will be 
fed at the discretion of the attending physician (standard care). 
 
Outcome Measures 
 
Primary endpoints 
The two primary endpoints of this RCT are (i) the incidence of new infections during PICU stay and (ii) 
the duration of PICU dependency. The latter will be reported as the crude number of PICU stay days 
and as the time to live discharge from PICU, to account for mortality as a competing risk.  
Also, the proportion of patients from the intention-to-treat population who stayed 8 days or more in PICU 
will be reported. This is not only reflecting the proportion of prolonged critically ill patients but also 
examines effects of the randomized intervention beyond the time window of the randomized intervention 
in PICU.   
The incidence of new infections for all patients in the three centers will be scored in consensus by the 
same two assessors (infectious disease specialists), who are blinded for treatment allocation. This 
assessment is based on an a priori drafted protocol [19], which makes use of prescribed antibiotics and 
clinical infection and inflammation data.  
As the timing of PICU discharge to a regular ward may be affected by the availability of beds on regular 
wards, which could induce bias, we a priori decided to analyze “time to discharge from PICU” as “time to 
ready for discharge from PICU”. A patient is considered “ready for discharge” as soon as all clinical 
  
113 
 
conditions for PICU discharge have been fulfilled (no longer in need for, or at risk of, vital organ 
support).  
 
Secondary safety endpoints 
Secondary safety endpoints comprise (i) death during PICU stay and during the time window of the 
randomized intervention (up to day 8), (ii) the proportion of patients with at least one episode of severe 
hypoglycemia (< 40 mg/dl), (iii) in-hospital mortality and (iv) 90-day mortality. As a specific serious 
adverse event (SAE), hypoglycemia resistant to bolus administration of glucose during the time window 
of the randomized intervention will be reported for both groups. 
 
Secondary efficacy endpoints 
1. Time to (live) discharge from hospital and duration of hospital stay, for both the index 
hospitalization and total hospitalization including stay in the referred hospital. 
2. Time to final (live) weaning from mechanical respiratory support and duration of mechanical 
ventilation  
3. Kidney failure. Proportion of patients in need for renal replacement therapy (RRT) during PICU stay 
and the duration of RRT (for those patients requiring RRT). Also the further analysis of the 
maximum and daily serum level of creatinine and urea during the intervention window and during 
PICU-stay will be reported. Other plasma and urine markers of kidney function will be investigated. 
4. Need for pharmacological or mechanical hemodynamic support during PICU stay and duration of 
such need. In addition, time to final (live) weaning from all pharmacological or mechanical 
hemodynamic support in PICU will be analyzed.  
5. Number of readmissions to the PICU. The proportion of patients readmitted within 48 hours after 
discharge will be recorded. Also the proportion of patients readmitted to the PICU beyond 48 hours 
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during their index hospital stay will be reported, as these patients will have been excluded from 
treatment allocation and will receive standard care.  
6. Liver dysfunction. Markers of liver function will be measured and proportion of patients with 
abnormal tests will be compared. 
7. Inflammation. Effect of the intervention on inflammation will be analyzed by comparing markers of 
inflammation. Both peak values and time courses will be analyzed. 
8. Duration of antibiotic treatment. The duration of antibiotic treatment (whenever given) within the 
intervention window and during the PICU-stay will be compared between the groups.  
9. Nutrition delivered during PICU-stay. The macronutrients and calories administered during the 
intervention window and thereafter during PICU-stay will be compared between the treatment 
groups. Total amount of macronutrients as well as the amounts administered parenterally and 
enterally will be reported.  
10. Structural and functional differences in muscle tissue during PICU stay. By ultrasonography, 
skeletal muscle thickness of the quadriceps, as a marker of muscle wasting, will be reported in a 
subset of patients. In addition, handgrip strength will be measured in a subset of patients older than 
6 years.  
11. Intolerance to enteral feeding during PICU-stay. Markers of tolerance to enteral feeding will be 
determined in a subset of patients. Markers in blood, stool and buccal swab samples will be 
investigated. 
 
Further pre-planned studies (execution depending on further funding), of which the detailed protocols 
and the methods for statistical analysis will be reported separately, are here listed below: 
 
1. Direct healthcare-related costs. Total, direct healthcare costs during index PICU stay  will be 
compared between the treatment groups [26].  
  
115 
 
2. Mechanistic studies. Explanations of any observed effects of delayed administration of PN as 
compared with standard of care will be assessed. These will comprise, among others, metabolic, 
endocrine, inflammation and (epi)genetic analyses, the investigation of the role of severity of 
illness, the use of indirect calorimetry, the type of blood glucose management, and post-
randomization factors such as type and dose of administered macronutrients, and disease 
evolution [27]. 
3. Long-term follow-up. This will include developmental and neurocognitive assessments, metabolic, 
endocrine, inflammation and (epi)genetic studies, with a healthy matched control group 
investigated over time in parallel.  
 
Data collection following recruitment 
All systemically applied medications received by the patients during the stay in PICU are registered. 
Every day the amount of kilocalories, carbohydrates, lipids and proteins delivered by either PN or EN 
are calculated and entered into the electronic case record form (eCRF). The need for and the number of 
days of mechanical ventilatory support, of mechanical and pharmacological hemodynamic support, of 
renal replacement therapies, days on antibiotics and days requiring a central line are recorded. Blood, 
urine, buccal mucosa swabs and hair samples are taken upon PICU admission and during PICU-stay. 
Such samples are appropriately handled (collected on ice when required) and immediately stored (at 
room temperature or at -20°C/-80°C as appropriate) for future measurements. Analyses on blood and 
urine for the primary clinical analyses include routine chemistry, hematology, and markers of 
inflammation. Further metabolic, endocrine, inflammatory and (epi)genetic measurements on stored 
samples in the context of mechanistic analyses are planned. For mechanistic and exploratory studies, 
ultrasound evaluation of the skeletal muscle, in combination with muscle strength measurements will be 
performed in a subset of patients [28-30]. Quality of life on admission and after 4-6 months is recorded 
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through a validated, semi-structured questionnaire, filled out by the parents, which is repeated at 2 and 
4 years after enrolment in the PEPaNIC trial.  
 
Data handling and record keeping 
Data are collected electronically in an anonymized eCRF, unambiguously linked to the source file. Data 
are manually transferred and checked for accuracy into the eCRF by the clinical research assistants’ 
team on a daily basis. Extensive range and consistency checks are performed by the study monitor. All 
original records, such as consent forms, eCRFs and relevant correspondence, will be archived at the 
participating centers, according to the local regulations. Vital status at 90 days (and at later follow-up 
times) will be recorded for all patients, by the National Death Registries. When this information is not 
available, vital status will be checked through the hospital information system or the regional network of 
pediatricians and general practitioners. 
All data are stored anonymously. Investigators involved in the trial do not have direct access to the 
database. In addition, the study monitor has logged the use of the database. After the trial, the study 
monitor will store all data in a secured file that is only accessible by the study monitor himself.  
 
Trial Organization 
The sponsor (KU Leuven) provides direct access to the eCRF, the source data and the study master file 
for monitoring, for review by the independent ethics committee and regulatory inspection. The sponsor 
established an independent data safety monitoring board (DSMB). The sponsor appointed one monitor. 
The monitor verifies that the trial is performed in accordance to the protocol as described in the 
European Medicine Agency's "Note for guidance on good clinical practice CPMP/ICH/135/95." as well 
as the Declaration of Helsinki. Monitoring is performed and reported according to the sponsor's standard 
operating procedures. The clinical research team guarantees a daily follow-up of patient screening and 
inclusion, availability of requested clinical data in the clinical patient files and protocol compliance. Non-
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compliance to the protocol and other questions or problems are reported to the study monitor and 
discussed with the principal investigators and trial steering committee. SAEs are reported to the study 
sponsor and, if needed, to the local ethics committee. The study monitor regularly provides the sponsor 
and the DSMB with reports on inclusions and SAEs. Regular meetings are organized with principal 
investigators and clinical research teams to discuss the daily progression of the PEPaNIC trial. 
 
The protocol has been instructed in each hospital to all clinical medical and nursing staff through 
frequent teaching sessions and clinical feedback rounds. The protocol decision support is integrated into 
the PICU PDMS in Leuven and Rotterdam, facilitating the prescription of the exact amounts of PN and 
EN according to protocol and clinical evolution. 
In order to achieve adequate participant enrolment to reach target sample size, regular meetings and 
site visits take place every 3 months together with the Rotterdam team and via teleconferences with the 
Edmonton team. 
 
Regular data auditing is done by the administrative trial team, the DSMB and by the central independent 
audit procedure in place at the University Hospital of Leuven in compliance with the European Trials 
Directives.  
 
Statistical analysis plan 
 
One consort diagram will be reported. 
 
Protocol compliance will be documented by comparing the actual amounts of PN and EN during the 
intervention window and this will be reported as absolute numbers of calories and weight units.  
For the primary and secondary endpoints taking place during PICU stay all data will be available. In 
case of request for discontinuation of the study intervention by patients, parents or legal guardians, this 
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will be respected, but all data will be analyzed. In case of consent withdrawal, the parents will be asked 
whether the data can be used for analysis.  In case this would not be allowed, all data of that patient will 
be removed from the database, and this will be reported in the consort diagram. At all time, the intention 
to treat principle will be respected and reported. No data imputation will be undertaken for any of the 
primary or secondary outcomes. 
 
Variables will be summarized as frequencies and percentages, means and standard errors of the 
means, or medians and interquartile ranges, as appropriate.  
 
Results will be analyzed with the use of chi-square testing, Student’s t-test or non-parametric testing 
(Wilcoxon rank-sum test, Van der Waerden test or Median test), as appropriate. Kaplan-Meier plots will 
be used to document time-to-event effects, and the time-to-event effect size will be estimated with the 
use of Cox proportional-hazard analysis. All time-to-event analyses will also be performed on data 
censored at 90 days. As death is a competing risk for duration of care outcomes, non-survivors will be 
censored beyond the longest duration of such care required for survivors [19]. All outcomes will be 
analyzed both with and without adjustment for baseline risk factors, including the diagnostic and age 
groups, severity of illness, severity of nutritional risk and center. The latter is considered necessary to 
account for the differences among centers in nutrition given to the control group and the variation in 
blood glucose control targets.  For these analyses, p-values will be considered significant when at or 
below 0.05 without correction for multiple comparisons. To assess whether any eventual impact of the 
intervention on the primary endpoints is affected by the baseline risk factor subgroups, interaction p-
values will be calculated (logistic regression or Cox proportional hazard analysis) with a threshold for 
significance of interaction set at a p-value of <0.1.  All analyses will be conducted on an intention-to-
treat basis. 
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SAMPLE SIZE CALCULATION AND INTERIM ANALYSES 
 
In the design phase of the PEPaNIC trial, and based on the previous adult EPaNIC trial results, the 
sample size (N=1440, 720 patients per arm) was determined in order to detect a reduction in the 
incidence of new infections during PICU stay from 20% to 15% (Absolute Risk Reduction 5%), with at 
least 80% one-tailed power and at least 70% two tailed power and at an alpha error of 5%. With this 
sample size, the trial can also detect a major safety issue, such as a doubling of the PICU mortality rate 
from 4% (the baseline mortality in the Leuven center) to 8% with a statistical power of 89% in a two-
sided test with an alpha error of 5%. This sample size will also allow to detect a reduction in mean 
duration of stay in PICU of 1 day with at least 90% power (2-tailed) and 95% certainty. 
Two interim analyses of the safety endpoints (except 90 day mortality) only were planned (after 
inclusion of 480 upon specific request of the DSMB, and after inclusion of 50% of the study population).  
It was a priori decided to determine the actual incidence of new infections during PICU stay in the three 
centers, as this was not known exactly for each of the participating centers prior to trial initiation. In 
order to allow statistical repowering and to judge the necessity of inclusion of more trial sites, the 
assessment of incidence of new infections during PICU stay in the control group took place after 
inclusion of 750 patients. Based on this actual incidence of new PICU infections in the control group, the 
hypothesized absolute risk reduction of 5% and an alpha error rate of 5%, the sample size of 1440 
patients (720 patients in each arm) was found sufficiently large to yield a statistical power of 77% two-
sided and of 85% one-sided. As these interim analyses did not assess any of the efficacy endpoints, no 
adjustments of the p-values are needed.  
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Discussion 
 
The clinical evidence for the administration of PN in critically ill children is missing [18]. Thousands of 
children are annually exposed to this non-evidence based treatment, which is assumed to result in 
faster recovery (benefit). This large international RCT will help PICU physicians to get more insight on 
the possibility of the omission of PN during the first week of critical illness. A significant difference in the 
safety and/or efficacy endpoints will provide important evidence for optimizing clinical patient care. Also 
a neutral result will provide important insight, as this would mean that clinicians can safely withhold PN 
in all comparable patients during the first week of ICU stay, which would have an impact on healthcare 
spending in the PICU. 
 
TRIAL STATUS  
 
The study was initiated as planned on June 18, 2012. At the time of the safety interim analyses (after 
480 and 750 study patients discharged from PICU), the DSMB advised the continuation of the trial and 
ratified the initial sample size of 1440 patients as adequate to test the hypothesis. On 1 December 2014, 
1130 patients have been included into the PEPaNIC trial. Recruitment of the last patient is expected for 
October 2015.  
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Abstract  
 
Background 
In critically ill children, the impact of early parenteral nutrition on clinical outcomes is unclear. In adults, 
recent trials have questioned the benefit of early parenteral nutrition.  
Methods 
This multi-center randomized controlled trial of 1440 critically ill children investigated whether 
withholding parenteral nutrition for 1 week (late parenteral nutrition) in the pediatric intensive care unit 
(PICU), while providing similar fluid loading, is clinically superior to early parenteral nutrition. In 723 
patients in the early parenteral nutrition group, parenteral nutrition was initiated within 24 hours, 
whereas the 717 patients in the late parenteral nutrition group did not receive parenteral nutrition before 
day 8. In both groups, enteral nutrition was attempted early, and intravenous micronutrients were given. 
Results 
Whereas mortality rates were similar, late parenteral nutrition reduced the proportion of patients with a 
new infection from 18.5% with early parenteral nutrition to 10.7% [Adjusted Odds Ratio 0.48 (95%CI 
0.35-0.66)]. Late parenteral nutrition also reduced the duration of PICU stay from a mean±SEM 9.2±0.8 
days to 6.5±0.4 days, with a higher likelihood of an earlier live discharge from PICU at any time 
[Adjusted Hazard Ratio 1.23 (1.11-1.37)]. Late parenteral nutrition reduced the duration of mechanical 
ventilatory support (P=0.001), the proportion of patients on renal replacement therapy (P=0.038) and the 
duration of hospital stay (P=0.001). Late parenteral nutrition lowered plasma gamma-
glutamyltransferase (P=0.001) and alkaline-phosphatase (P=0.036) concentrations and increased 
plasma bilirubin (P=0.004) and C-reactive-protein (P=0.006).  
Conclusion 
In critically ill children, omitting parenteral nutrition for 1 week was clinically superior to providing early 
parenteral nutrition. 
ClinTrials.gov Identifier NCT01536275 
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Background  
 
Critically ill children cannot be fed normally by mouth, which often results in a pronounced macronutrient 
deficit after a few days. This macronutrient deficit has been associated with infections, weakness, 
prolonged mechanical ventilation and delayed recovery.1-3 In order to prevent or reduce this 
macronutrient deficit, current guidelines, largely based on small studies with surrogate endpoints and 
expert opinion, advise that nutritional support be initiated soon after admission to the pediatric intensive 
care unit (PICU).4-6 The preferred route for providing nutrition in PICU is via a nasogastric tube7 but 
enteral nutrition is often delayed or interrupted.8,9 Children require relatively more macronutrients than 
adults as nutrition should equal basic metabolic needs and allow for growth. Hence, current standard of 
pediatric intensive care is to meet these requirements early.7,10 When enteral nutrition fails, parenteral 
nutrition is advised5,6 but concerns about parenteral nutrition overdosing11 explain why current nutritional 
practices in PICUs vary.8  
Randomized controlled trials (RCTs) that address, with adequate statistical power, the impact of 
parenteral nutrition on clinical outcomes in critically ill children are currently lacking.12 In critically ill 
adults, recent large RCTs have questioned the benefit of early parenteral nutrition.13-15 Therefore, in this 
international multicenter RCT, we investigated whether a strategy of withholding parenteral nutrition up 
to day 8 in the PICU (late parenteral nutrition) is clinically superior to the current practice of early 
parenteral nutrition.  
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Methods 
 
Study Design and Oversight 
The Pediatric Early versus Late Parenteral Nutrition In Critical Illness (PEPaNIC) study was a 
multicenter prospective, randomized, controlled, parallel-group superiority trial (ClinTrials.gov 
NCT01536275).16 The institutional/national ethical review boards of the participating sites approved the 
study protocol and the consent forms. The study protocol and statistical analysis plan are available at 
www.NEJM.org, and have been reported.16 The first and last authors vouch for the fidelity of the study 
to the protocol. 
 
Patients 
From June 18, 2012 through July 27, 2015 all children (term newborn to 17 years old), who were 
admitted to one of the participating PICUs were eligible for inclusion, if a PICU stay of minimal 24 hours 
was expected, a STRONGkids nutritional risk score of two points or more was present,17 and if none of 
the exclusion criteria were met (Supplementary_Appendix,_Table_1). Informed consent was requested 
from the parents or legal guardians prior to elective admissions. For emergency admissions, the parents 
or legal guardians were approached for informed consent within 24 hours after PICU admission. 
Per center, consecutive, eligible patients were randomly assigned to one of the two treatment arms in a 
1-to-1 ratio. Concealment of the allocation to the randomized treatment was ensured by a central 
computerized randomization system. The randomization was stratified, in permuted blocks of 10, by age 
(<1 and ≥1 year) and diagnosis upon admission (medical–neurological, medical-other, surgical-cardiac 
and surgical-other). The block size was unknown to the medical and research team.  
Outcome assessors and investigators not directly involved in patient intensive care were blinded to 
treatment allocation. 
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The Independent Data and Safety Monitoring Board (DSMB) planned to perform 2 interim analyses of 
the safety endpoints, 1 after inclusion of 480 patients and a second after inclusion of 50% of all patients. 
The DSMB advised that recruitment could be continued to completion.  
 
Study Procedures 
All participating centers used early parenteral nutrition as the standard of care. In patients assigned to 
the early parenteral nutrition group (control group), parenteral nutrition was initiated within 24 hours after 
PICU admission in a dose and composition that varied according to local guidelines (Supplementary 
Appendix, _Table_2)16 and that supplemented any enteral nutrition up to local macronutrient and caloric 
targets (Supplementary_Appendix, _Table_3).  
 
In patients allocated to the late parenteral nutrition group (intervention group), parenteral nutrition was 
withheld up to the morning of day 8 in the PICU. To match the fluid administration of the control group, 
taking into account the volume of enteral nutrition delivered, a mixture of dextrose 5% and saline was 
provided.16 When blood glucose concentrations spontaneously dropped below 50 mg/dL in the late 
parenteral nutrition group, dextrose 5% was switched to 10% until blood glucose exceeded 80 mg/dL 
and remained stable.16 
 
In both treatment groups equally, enteral nutrition was initiated early and increased according to local 
guidelines. Both groups also received intravenous micronutrients (trace elements, minerals and 
vitamins) from day 2 onwards until enteral nutrition reached 80% of the caloric targets. From the 
morning of day 8 in PICU onward, supplementary parenteral nutrition was provided for those patients in 
both groups who were not yet receiving 80% of the caloric target enterally. In Leuven, insulin infusion 
was started in both groups to target blood glucose concentrations of 50-80 mg/dL for infants (aged <1y) 
and 70-100 mg/dL for children (aged ≥ 1 year). In Rotterdam, all patients received insulin infusion to 
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target blood glucose concentrations of 72-145 mg/dL, except for patients with traumatic brain injury for 
whom the target was 108-145 mg/dL. In Edmonton, patients received insulin infusion when blood 
glucose levels exceeded 180 mg/dL.  
 
Data Collection 
All patient data were stored in a logged database that was closed 90 days after inclusion of the last 
patient. At baseline, the two randomization groups were comparable (Table 1).  As the Pediatric Risk of 
Mortality could not be used as a baseline severity of illness score, given that treatment allocation 
expectedly affected the highest blood glucose concentration during the first 24h, the Pediatric Logistic 
Organ Dysfunction (PELOD) score of the first 24h was used instead. The admission risk of malnutrition 
was quantified with use of the STRONGkids score, dichotomized for “medium risk” (score 2 and 3) and 
“high risk” (score 4 and 5).17 Presence of an infection upon PICU admission and of any new infection 
acquired after randomization was judged in consensus by two infectious disease specialists who were 
blinded for treatment allocation, with use of an a priori-drafted protocol 
(Supplementary_Appendix,_Table_4).13 Daily records were kept regarding all intensive care 
procedures, treatments, nutrition and laboratory results. Information on vital status at 90 days was 
obtained from National Death Registries, hospital information systems and regional networks of 
pediatricians and general practitioners.  
 
Outcome Measures 
Primary Endpoints 
The two primary endpoints were new infection acquired during PICU stay and the duration of PICU 
dependency, adjusted for 5 predefined baseline risk factors (diagnostic groups, age group, severity of 
illness, severity of nutritional risk and center).16 For patients with a new infection, the duration of 
antibiotic treatment was compared. The duration of PICU dependency was quantified as the number of 
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PICU days and as time to live discharge from PICU to account for mortality as a competing risk. 
Discharge from PICU was a priori defined as the moment when patients were ready for PICU discharge 
(no longer requiring, or at risk of requiring, vital organ support).16  
 
Secondary Safety Endpoints 
Death during the time window of the randomized intervention (first 7 days in PICU), during PICU stay, 
during index hospitalization and at the 90-day landmark, the number of patients with hypoglycemia 
(below 40 mg/dL) and the number of readmissions to the PICU within 48h were secondary safety 
endpoints.  
 
Secondary Efficacy Endpoints 
Secondary efficacy outcomes were time to final (live) weaning from mechanical ventilatory support, 
duration of pharmacological and/or mechanical hemodynamic support, proportion of patients receiving 
renal replacement therapy (RRT), markers of liver dysfunction and inflammation and time to (live) 
discharge from the hospital.  
 
Statistical Analyses 
The sample size (N=1440, 720 patients per arm) was calculated to detect a 5% absolute reduction in 
the proportion of patients with a new infection (from an estimated baseline of 20%) with at least 70% 
two-tailed power and an alpha error of 5%.  
 
All analyses were conducted on an intention-to-treat basis.  
 
Variables were summarized as frequencies and percentages, medians and interquartile ranges, or 
means and standard errors (SEM). Univariable comparisons were done with use of the chi-square test 
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(Fisher Exact) and by the Wilcoxon rank-sum test. Kaplan-Meier plots were used to illustrate time-to-
event effects with univariable significance analyzed by log-rank testing. The time-to-event effect size 
was estimated with use of Cox Proportional Hazard Analysis, censored at 90 days. To take into account 
death as a competing risk for duration of care outcomes, non-survivors were censored beyond all 
survivors at 91 days. These time-to-event outcomes were assessed univariably and with adjustment for 
the baseline risk factors (diagnostic groups, age group, severity of illness, severity of nutritional risk and 
center). The adjusted multivariable analysis of the impact of the intervention on dichotomized outcomes 
was done with Logistic Regression Analysis. 
 
All P-values were 2-sided and considered significant when <0.05. No corrections for multiple 
comparisons were done. As the interim analyses did not assess efficacy endpoints, no adjustment of the 
P-value threshold for significance was required.  
 
To assess whether the impact of the intervention on the primary endpoints was affected by the baseline 
risk factor subgroups, interaction P-values were calculated (Multivariable Logistic Regression Analyses 
and Multivariable Cox Proportional Hazard Analyses) with a threshold for significance of interaction set 
at a P-value of <0.1.   
 
All analyses were performed with the use of JMP software version 11.2.0 (SAS Institute). 
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Results  
 
Study Intervention 
A total of 1440 patients underwent randomization and were included in the analysis (Fig.1). Caloric and 
macronutrient intake per day up to day 16 in the PICU, illustrating protocol compliance, is shown in 
Figure 2 (Supplementary_Appendix,_Fig.S1_Fig.S2). 
 
Primary Outcomes 
With late parenteral nutrition, the proportion of patients who acquired a new infection was an absolute 
7.8% (95% CI 4.2%-11.4%) lower than with early parenteral nutrition (Table 2) [Adjusted Odds Ratio 
(OR) of 0.48 (95% CI 0.35-0.66)] (Table 3). This was mostly attributable to fewer patients acquiring an 
airway or blood stream infection in the late parenteral nutrition group (Table 2). Late parenteral nutrition 
also reduced the duration of stay in the PICU by a mean 2.7 (95% CI 1.3-4.3) days (Table 2), with a 
higher likelihood of an earlier live discharge from PICU at any time [Adjusted Hazard Ratio (HR) of 1.23 
(95% CI 1.11-1.37)] (Table 2, Fig. 3; Supplementary_Appendix,_Fig.3, 
Supplementary_Appendix,_Table_5). There were no significant (P<0.1) interactions between treatment 
allocation and any of the predefined risk factors (Supplementary_Appendix,_Table_6). However, the P-
value for interaction between randomized treatment allocation and the nutritional risk was 0.1 for new 
infections, with a greater reduction of infections with late parenteral nutrition in the high nutritional risk 
group [OR 0.28 (95% CI 0.10-0.70)] than in the medium nutritional risk group [OR 0.54 (0.38-0.76)]. 
There was also a higher likelihood of an earlier live discharge from PICU with late parenteral nutrition in 
the high nutritional risk group [HR 1.61 (95% CI 1.12-2.31)] than in the medium nutritional risk group 
[HR 1.19 (95% CI 1.06-1.33)] (interaction P=0.1).  
There was also no significant interaction between treatment allocation and age group. A post-hoc 
subgroup analysis of the 209 term neonates aged less than 4 weeks at time of inclusion revealed that 
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the benefits of late parenteral nutrition were similar or larger than for children aged 4 weeks or more [OR 
for new infections 0.47 (95% CI 0.22-0.95) for neonates versus 0.48 (95% CI 0.33-0.69) for older 
children, interaction P=0.9; likelihood of earlier live discharge from PICU HR 1.73 (95% CI 1.27-2.35) for 
neonates versus 1.17 (95% CI 1.04-1.31) for older children, interaction P=0.033].  
The impact of late PN on the primary outcomes was unaltered after adjusting for the amount of enteral 
nutrition (Supplementary_Appendix,_Table_7).     
 
Secondary Safety Outcomes 
Mortality rate was similar in both groups for all predefined time horizons (Table 2, Fig. 3). The proportion 
of patients with an episode of hypoglycemia below 40 mg/dL was higher in the late parenteral nutrition 
than in the early parenteral nutrition group (Table 2). Adjusting for hypoglycemia did not alter the effect 
size of late parenteral nutrition on the primary outcomes [OR for new infection 0.45 (95%CI 0.32-0.62) 
and likelihood of an earlier live discharge from PICU adjusted hazard ratio of 1.26 (95% CI 1.13-1.41)] 
(Supplementary_Appendix,_Table_7). Readmission to PICU within 48h and occurrence of serious 
adverse events were similar for the 2 randomization groups (Table 2).  
 
Secondary Efficacy Outcomes  
Late parenteral nutrition reduced the duration of mechanical ventilatory support and increased the 
likelihood of live weaning thereof (Table 2; Supplementary_Appendix,_Table_5 ), whereas the duration 
of hemodynamic support was unaltered. After adjustment for predefined risk factors, late parenteral 
nutrition also reduced the odds for renal replacement therapy (Table 2; 
Supplementary_Appendix,_Table_5). With late parenteral nutrition, the plasma total bilirubin levels 
peaked higher than with early parenteral nutrition during the intervention window (Table 2) and during 
the duration of PICU stay (Supplementary_Appendix,_Table_8), while plasma gamma-
glutamyltransferase and alkaline phosphatase levels peaked higher with early parenteral nutrition (Table 
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2). Other liver tests were unaltered (Table 2). Despite fewer new infections with late parenteral nutrition, 
plasma CRP concentrations peaked higher during the intervention window (Table 2). 
Duration of stay in the index hospital was a mean 4.1 (95% CI 1.4-6.6) days shorter, and the likelihood 
of an earlier live discharge from hospital was higher [Adjusted HR 1.19 (95% CI 1.07-1.33)] in the late 
parenteral nutrition group (Table 2, Fig. 3; Supplementary_Appendix,_Fig.3, 
Supplementary_Appendix,_Table_5). This effect of late parenteral nutrition remained significant when 
taking into account any eventual additional stay in a transferral hospital (Table 2, Fig. 3; 
Supplementary_Appendix,_Fig.3, Supplementary_Appendix,_Table_5). 
Adjusting for hypoglycemia or for the amount of enterally administered nutrition did not alter the impact 
of late parenteral nutrition on any of the secondary outcomes (Supplementary_Appendix,_Table_7). 
 
  
136 
 
Discussion 
 
We here demonstrated that withholding parenteral nutrition for one week in the PICU was clinically 
superior to early provision of parenteral nutrition, with fewer new infections, shorter duration of intensive 
care dependency and a shorter hospital stay.  
 
The clinical superiority of late parenteral nutrition was present irrespective of the diagnosis, severity of 
illness, nutritional risk and age of the child. The observation that critically ill children at highest nutritional 
risk benefited the most from withholding early parenteral nutrition was unexpected. However, this finding 
was reinforced by an apparently greater benefit of not providing parenteral nutrition early to critically ill 
term neonates than to older children. Indeed, immediate initiation of nutrition is advised for neonates 
because they are considered to have less metabolic reserve.7  
Late parenteral nutrition exerted its benefits irrespective of the variability in nutritional care and blood 
glucose management across participating centers. Late parenteral nutrition increased hypoglycemia but 
this did not affect its impact on outcome. Such brief episodes of hypoglycemia during pediatric critical 
illness or in premature/mature newborns also did not negatively affect long-term neurocognitive 
outcomes in earlier studies.18-20 
The finding that late parenteral nutrition substantially reduced new infections but increased inflammation 
as indicated by plasma CRP illustrates the limitation of surrogate endpoints for trials.21-25 As in a 
previous adult study, late parenteral nutrition reduced plasma gamma-glutamyltransferase and alkaline 
phosphatase also in children, suggestive of less cholestasis.13,26,27 However, late parenteral nutrition 
increased plasma bilirubin in these critically ill children as it did in adult patients, further supporting the 
concept that elevated plasma bilirubin in response to critical illness may be partially adaptive.28  
Underlying mechanisms of the clinical benefits observed with accepting a substantial macronutrient 
deficit early during critical illness in children remain speculative. Preservation of autophagy may play a 
  
137 
 
role given its importance for innate immunity and for quality control in cells with a long half-life such as 
myofibers.29-31  
 
A limitation of this study is that patients, their parents and the intensive care providers were aware of the 
treatment allocation. However, outcome assessors and caregivers on the pediatric wards were blinded. 
The strength of this study is the external validity, given the multicenter study design.  
 
In conclusion, In critically ill children, omitting parenteral nutrition for 1 week while giving micronutrients 
intravenously was clinically superior to providing early parenteral nutrition to supplement insufficient 
enteral nutrition.  
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FIGURE LEGENDS 
 
Figure 1. Consort Diagram 
Patients were excluded for several reasons, as listed in Supplementary_Table_1. NICU stands for 
Neonatal Intensive Care Unit, PICU for Pediatric Intensive Care Unit, PN for Parenteral Nutrition and 
DNR for a “Do Not Resuscitate” order.  
 
Figure 2. Caloric and Macronutrient Intake  
Daily amount of energy in kcal/day, and the daily amounts of substrates in g/day, for the first 16 days of 
pediatric intensive care (PICU) stay provided by the enteral route, the parenteral route or both (total). 
Bars represent the mean and the whiskers represent the standard error of the mean (SEM). The red 
bars represent the late parenteral nutrition (PN) group; the blue bars represent the early PN group.  
 
Figure 3. Kaplan-Meier plots for the time to discharge from the PICU and the hospital and for 
survival up to 90 days 
The panels A-C represent the cumulative proportions of patients discharged from the PICU (A) and from 
the hospital [index (B); total (C)]. Data for surviving patients were censored at 90 days while non-
survivors were censored at time of death. For sake of clarity, only the first 30 days are shown in panels 
A-C. Panel D illustrates survival up to 90 days. The red lines represent the late PN group; the blue lines 
represent the early PN group. *univariable log-rank P-value; $ P-value adjusted in multivariable 
analysis.  
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FIGURE 1 
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FIGURE 2  
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FIGURE 3 
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TABLE 1 
There were no statistically significant differences in baseline characteristics between treatment groups.  
 
 
Table 1. Baseline Characteristics   
 Early PN Late PN 
Total number of patients 723 717 
Age - yr (median - IQR) 1.4 (0.3-6.1) 1.5 (0.2-7.2) 
Infant (age <1 year) No (%) 328 (45.4) 325 (45.3) 
Male - No (%) 415 (57.4) 415 (57.9) 
Weight - kg (median - IQR) 10.0 (4.8-20.0) 10.3 (4.5-21.5) 
     SD score* (median - IQR) -0.5 (-1.4-0.5) -0.4 (-1.4-0.5) 
Height - cm (median - IQR) 80 (58-113) 80 (56-120) 
     SD score* (median - IQR) -0.3 (-1.5-0.8) -0.3 (-1.4-0.8) 
BMI SD score* (median -  IQR) -0.5 (-1.5-0.5) -0.5 (-1.6-0.6) 
STRONGkids   
     Medium risk (score 2 or 3) - No (%) 644 (89.1) 644 (89.8) 
     High risk (score 4 or 5) - No (%) 79 (10.93) 73 (10.18) 
PELOD first 24h in PICU (median - IQR) 21 (11-31) 21 (11-31) 
Emergency Admission - No (%) 383 (53.0) 400 (55.8) 
Diagnostic Groups - No (%)   
     Surgical   
          Abdominal 53 (7.3) 60 (8.4) 
          Burns 5 (0.7) 5 (0.7) 
          Cardiac 279 (38.5) 268 (37.3) 
          Neurosurgery – Traumatic Brain Injury 63 (8.7) 53 (7.3) 
          Thoracic 34 (4.7) 27 (3.8) 
          Transplantation 7 (1.0) 17 (2.4) 
          Trauma/Orthopedic 28 (3.9) 26 (3.6) 
          Other 21 (2.9) 27 (3.8) 
     Medical   
          Cardiac 30 (4.2) 31 (4.3) 
          Gastrointestinal/Hepatic 2 (0.3) 4 (0.6) 
          Oncologic/Hematologic 8 (1.1) 7 (1.0) 
          Neurologic 51 (7.1) 52 (7.3) 
          Nephrologic 1 (0.1) 1 (0.1) 
          Respiratory 99 (13.7) 96 (13.4) 
          Other 42 (5.8) 43 (6.0) 
Admission mechanical ventilation - No (%) 639 (88.4) 622 (86.8) 
Admission ECMO or other assist device – No (%) 19 (2.6) 25 (3.5) 
Admission with infection – No (%) 287 (39.9) 271 (37.8) 
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PN stands for Parenteral Nutrition, IQR for Interquartile Range, PELOD for PEdiatric Logistic Organ 
Dysfunction, PICU for Pediatric Intensive Care Unit, BMI for Body Mass Index, *Age- and gender 
specific standard deviation (SD) scores were calculated using WHO reference data 
(http://www.who.int/growthref/en/). 
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TABLE 2 
 
 
No censoring was applied for the unadjusted comparisons of duration of care outcomes. All adjusted 
duration of care outcomes were censored at 90 days with non-survivors censored at 91 days.  
PN stands for Parenteral Nutrition, PICU for Pediatric Intensive Care Unit, GGT for Gamma-
Glutamyltransferase, ALT for Alanine Aminotransferase, AST for Aspartate Aminotransferase, CRP for 
C-Reactive Protein,  OR for Odds Ratio, HR for Hazard Ratio, 95% CI for 95% confidence intervals,  
 
*Mean (Standard Error of the Mean).  
 
Table 2. Outcomes 
 Early PN Late PN P Value 
OR or HR  
adjustedº (95% CI) 
Late PN vs. Early PN 
P Value 
 N=723 N=717    
Primary Outcomes      
    Patients with New Infections – No (%) 134 (18.5) 77 (10.7) <0.001 0.48 (0.35-0.66) < 0.001 
        Airway 59 (8.2) 30 (4.2) 0.002   
        Blood Stream 23 (3.2) 10 (1.4) 0.03   
        Urinary Tract 7 (1.0) 2 (0.28) 0.17   
        Central Nervous System 3 (0.4) 2 (0.3) 1.00   
        Soft Tissue  7 (1.0) 4 (0.6) 0.54   
        Other Focus 5 (0.7) 8 (1.1) 0.42   
        No Focus Identified 30 (4.1) 21 (2.9) 0.25   
    Total Duration Antibiotic Treatment when Infected – Days*  21.3 (3.1) 17.4 (1.9) 0.77   
    Total Duration of Stay in PICU$       
        Days* 9.2 (0.8) 6.5 (0.4) 0.002 1.23 (1.11-1.37) < 0.001 
        Patients Requiring at least 8 Days in PICU - No (%) 216 (29.88) 159 (22.2) <0.001   
Secondary Safety Outcomes      
    Non-survivors - No (%)      
        Within 8 Days in PICU 21 (2.9) 19 (2.6) 0.87 0.73 (0.34-1.51) 0.39 
        During PICU Stay 36 (5.0) 32 (4.5) 0.70 0.73 (0.42-1.28) 0.27 
        During Hospital Stay 44 (6.1) 37 (5.2) 0.49 0.72 (0.43-1.19) 0.20 
        Within 90 days after enrollment 49 (6.8) 38 (5.3) 0.26 0.64 (0.39-1.05) 0.07 
Patients with Hypoglycemia <40 mg/dL During Intervention - No (%) 35 (4.8) 65 (9.1) 0.001   
SAE (hypoglycemia refractory to treatment for 2h) - No (%) 0 (0.000) 1 (0.001) 1.00   
Readmissions to PICU within 48h - No (%) 9 (1.2) 13 (1.8) 0.39   
Secondary Efficacy Outcomes      
    Duration of Mechanical Ventilatory Support - Days* 6.4 (0.7) 4.4 (0.3) 0.01 1.19 (1.07-1.32) 0.001 
    Duration of Hemodynamic Support - Days * 3.0 (0.3) 2.4 (0.2) 0.35   
    Kidney Failure      
        Renal Replacement Therapy - No (%) 26 (3.6) 18 (2.5) 0.28 0.49 (0.24- 0.96) 0.03 
    Liver Dysfunction (during intervention window)*      
        Highest plasma Bilirubin - mg/dL (N=1252 ) 1.4 (0.1) 1.7 (0.1) 0.004   
        Highest plasma Alkaline Phosphatase- IU/L  (N=1234) 171 (3) 171 (5) 0.03   
        Highest plasma GGT - IU/L (N=1217) 59 (6) 45 (3) 0.001   
        Highest plasma ALT - IU/L (N=1260) 72 (8) 113 (20) 0.64   
        Highest plasma AST - IU/L (N=1259) 179 (26) 263 (48) 0.69   
    Inflammation (during intervention window)*      
        Highest plasma CRP - mg/L (N=1296) 79 (4) 90 (4) 0.006   
    Duration of Stay in Hospital*      
        Index Hospital - Days 21.3 (1.3) 17.2 (1.0) 0.005 1.19 (1.07-1.33) 0.001 
        Total (Index + Transferral Hospital) - Days 22.6 (1.3) 18.6 (1.0) 0.010 1.21 (1.08-1.34) < 0.001 
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$The duration of stay in the PICU was defined as the time from admission of patients until patients were 
ready for discharge. Patients were considered ready for discharge as soon as all clinical conditions for 
ICU discharge were fulfilled (i.e., no longer requiring, or at risk of requiring, vital-organ support) 
ºAdjusted for the following risk factors: center, age group, diagnosis group, PELOD score (first 24h) and 
STRONGkids category 
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Supplementary Figure 1. Caloric and macronutrient intake per kg 
Daily amount of energy in kcal/kg/day, and the daily amounts of substrates in g/kg/day, for the first 16 
days of pediatric intensive care unit (PICU) stay provided by the enteral route, the parenteral route or 
both (total). Bars represent the mean and the whiskers represent the standard error of the mean (SEM). 
The red bars represent the late parenteral nutrition (PN) group; the blue bars represent the early PN 
group.  
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Supplementary Figure 2. Caloric intake per kg for weight categories 
Daily amount of energy in kcal/kg/day, for three weight categories (<10 kg, 10-20 kg and >20 kg), for the 
first 16 days of pediatric intensive care unit (PICU) stay provided by the enteral route, the parenteral 
route or both (total). Bars represent the mean and the whiskers represent the standard error of the 
mean (SEM). The red bars represent the late parenteral nutrition (PN) group; the blue bars represent 
the early PN group.  
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Supplementary Figure 3. Kaplan-Meier plots for the time to (live) discharge from the PICU and the 
hospital and for survival up to 90 days 
Panels A to F represent the cumulative proportions of patients discharged from the PICU (A), 
discharged live from the PICU (B), discharged from the hospital [index (C) and total (E)] and discharged 
live from the hospital [index (D) and total (F)]. For the analyses of the time to discharge, data for all 
patients were censored at 90 days, while non-survivors were censored at time of death. For the 
analyses of the time to live discharge, data were censored at 90 days with non-survivors censored at 91 
days to account for death as a competing risk. For sake of clarity, only the first 30 days are shown in 
panels A-F. Panel G illustrates survival up to 90 days. The red lines represent the late PN group; the 
blue lines represent the early PN group.  
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*univariable log-rank P-value; $ P-value adjusted in multivariable analysis. 
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Supplementary Table 1. Exclusion criteria for study participation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PICU=Pediatric Intensive Care Unit, PN=Parenteral Nutrition  
  
Not critically ill enough to necessitate nutritional support 
STRONGkids score lower than 2 on PICU admission1 
Non-pediatric patients (aged 17 or older) 
Premature newborns (<37 weeks gestational age upon admission in the PICU) 
‘Do not resuscitate’ code at the time of PICU admission 
Expected death within 12 hours 
Readmission to PICU after already having been randomized 
Enrollment in another intervention trial 
Transfer from another PICU or neonatal ICU after a stay of more than 7 days 
Ketoacidotic or hyperosmolar coma 
Inborn metabolic diseases requiring specific diet 
Short bowel syndrome or other conditions requiring PN for more than 7 days prior to PICU 
admission 
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Supplementary Table 2. Local protocols for initiation of PN in early PN group, in all participating 
centers EN was attempted as soon as possible 
 
 
 
EN=enteral nutrition, IV=intravenous, PN=parenteral nutrition 
 
 
 
 
 
 
 
 
 
 
  
 
Center On admission Day 2 Day 3 Subsequent Stay 
Leuven, 
Belgium 
Mixture of glucose 30% 
and Vaminolact® 
(Fresenius) 
Addition of lipids 
(SMOFlipid® Fresenius) 
All replaced by mixture of 
glucose 50% and 
SMOFlipid® with 
Vaminolact® or Vamin 18®. 
Glucose 50% and 
SMOFlipid® with 
Vaminolact® or Vamin 18® 
Rotterdam, 
The 
Netherlands 
Continuous glucose 
infusion with glucose 
intake 4-6 mg/kg/min  
(< 30 kg) or 2-4 
mg/kg/min (> 30 kg) 
Pharmacy-made PN: 
mixture of glucose, 
Primene® (Baxter) and 
Intralipid® (Baxter, 50% of 
final dose). Children >30 
kg Olimel® (Baxter, N5 or 
N4 depending on central 
or peripheral line) 
Increase of lipids to 100% Pharmacy-made PN: 
mixture of glucose, 
Primene® (Baxter) and 
Intralipid® (Baxter, 100% of 
final dose). Children >30 kg 
Olimel® (Baxter, N5 or N4 
depending on  central or 
peripheral line) 
Edmonton, 
Canada 
Continuous glucose 
infusion with glucose 
intake 3-4 mg/kg/min 
Addition of 20% IV lipids 
(50% of final dose) 
Increase of lipids to 100% 
Mixture amino acids and 
concentrated glucose  
Mixture amino acids, 
concentrated glucose and 
20% IV lipids  
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Supplementary Table 3. Macronutrient and caloric targets per center 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EN=enteral nutrition, PN=parenteral nutrition 
 
Center First day Subsequent stay 
Leuven, Belgium First 10 kg: 100 kcal/kg 
10-20 kg: + 50 kcal/kg 
>20 kg: + 20 kcal/kg 
(adjusted downward when fluid restriction required) 
Rotterdam,  
The Netherlands 
EN: basal metabolic rate 
by Schofield-weight2 
PN: ESPGHAN3 
EN: Recommended Dietary 
Allowances4 
PN: ESPGHAN3 
Edmonton, Canada Resting energy 
expenditure by indirect 
calorimetry 
If indirect calorimetry 
impossible: 65% of basal 
metabolic rate (FAO-
WHO5) 
Adjusted daily by the 
dietitian based on clinical 
information 
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Supplementary Table 4. Protocol for scoring of infections    
 
1. Data export  
All patients receiving antimicrobial agents were identified by the datamanager, who provided an 
export of all patient numbers with all the information on antimicrobial agents given as well as the 
duration of such treatment. 
 
2. Identification of patients with infections 
The infectious disease specialists, who were blinded for treatment allocation, selected all 
patients receiving antimicrobial agents for more than 48h, after excluding all patients who 
received prophylaxis. Each patient who fulfilled the criteria for infection, as well as the type of 
infection, was identified as such based on thorough review of the medical record6. Patients for 
whom antimicrobials where initiated prior to PICU admission or within the first 48 hours of 
admission while the criteria for infection were fulfilled, were labeled as “having an infection upon 
admission”. When antimicrobial agents were initiated after randomization and beyond the first 
48 hours in the PICU, and were given for more than 48 hours while the criteria for infection were 
fulfilled, the patient was labeled as “having a new infection”6.  
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Supplementary Table 5. Logistic regression and Cox proportional hazards analyses 
 
 
All duration of care outcomes were censored at 90 days with non-survivors censored at 91 days. 
OR=Odds Ratio, HR=Hazard Ratio, PN=parenteral nutrition, 95% CI= 95% confidence intervals, 
PICU=pediatric intensive care unit 
* Adjusted for the following risk factors: center, age group, diagnosis group, PELOD score (first 24h)7 
and STRONGkids category1 
 
 
OR or HR 
unadjusted (95% CI) 
Late PN vs. Early PN 
P-value 
unadjusted 
OR or HR  
adjusted* (95% CI) 
Late PN vs. Early PN 
P-value 
adjusted 
Primary Outcomes     
Odds for New Infection 0.53 (0.39-0.71) < 0.001 0.48 (0.35-0.66) < 0.001 
Likelihood of Earlier Live Discharge 
from PICU  
1.14 (1.02-1.27) 0.01 1.23 (1.11-1.37) < 0.001 
Safety Outcomes     
Odds for Death     
   Within 8 days in PICU 0.91 (0.48-1.71) 0.76 0.73 (0.34-1.51) 0.39 
   During PICU Stay 0.89 (0.55-1.45) 0.64 0.73 (0.42-1.28) 0.27 
   During Hospital Stay 0.84 (0.53-1.32) 0.44 0.72 (0.43-1.19) 0.20 
   Within 90 days after enrollment 0.77 (0.49-1.19) 0.23 0.64 (0.39-1.05) 0.07 
Secondary Efficacy Outcomes     
Likelihood of Earlier Live Weaning 
from Mechanical Ventilatory Support 
1.11 (1.00-1.24) 0.04 1.19 (1.07-1.32) 0.001 
Odds for Renal Replacement 
Therapy 
0.69 (0.37-1.26) 0.23 0.49 (0.24- 0.96) 0.03 
Likelihood of Earlier Live Discharge 
from Index Hospital 
1.14 (1.03-1.27) 0.01 1.19 (1.07-1.33) 0.001 
Likelihood of Earlier Live Discharge 
from Hospital (Index and Transferral 
Hospital) 
1.14 (1.02--1.27) 0.02 1.21 (1.08-1.34) <0.001 
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Supplementary Table 6. P-values for interaction between randomized treatment allocation and the 
predefined baseline risk factors on the primary outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PELOD=PEdiatric Logistic Organ Dysfunction7,  PICU=Pediatric Intensive Care Unit  
1 Multivariable Logistic Regression Analysis censored at 90 days with non-survivors censored at 91 days 
2 Multivariable Cox Proportional Hazard Analysis censored at 90 days with non-survivors censored at 91 
days 
 
 
 P-value 
Patients with New Infections1  
  PELOD score first 24h in PICU 0.80 
  Age group 0.55 
  Diagnostic group 0.25 
  STRONGkids score1 0.11 
  Center 0.72 
Time to live discharge from the PICU2  
  PELOD score first 24h in PICU 0.80 
  Age group 0.65 
  Diagnostic group 0.73 
  STRONGkids score1 0.19 
  Center 0.56 
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Supplementary Table 7. Adjusted Odds Ratios and Hazard Ratios further corrected for hypoglycemia 
(plasma concentration glucose < 40 mg/dL) and for the amount of of enteral feeding (kcal/kg/day) during 
randomisation window  
 
 
 
All duration of care outcomes were censored at 90 days with non-survivors censored at 91 days. 
OR=Odds Ratio, HR=Hazard Ratio, PN=Parenteral Nutrition, 95% CI= 95% Confidence Intervals, 
PICU=Pediatric Intensive Care Unit 
 
* Adjusted for the following risk factors: center, age group, diagnosis group, PELOD score first 24h7, 
STRONGkids category1 and hypoglycemia (plasma concentration glucose < 40 mg/dL) or amount of 
enterally adminstered kcal per kg per day. 
 
In both analyses, experiencing hypoglycemia and receiving a higher amount of enterally adminstered 
kcal per kg per day were independent risk factors for infections and for a delayed live discharge from 
PICU (all P≤0.004). 
 
 
 
 OR or HR adjusted* 
(95% CI) 
Late PN vs. Early PN 
(adjusted 
for 
hypoglycemia) 
P-value 
 
OR or HR adjusted* 
(95% CI) 
Late PN vs. Early 
PN 
(adjusted 
for 
enteral kcal/kg/d) 
P-value 
Primary Outcomes     
Patients with New Infections 0.45 (0.32-0.62) < 0.001 0.47 (0.34-0.65) < 0.001 
Likelihood Earlier Live PICU 
Discharge  
1.26 (1.13-1.41) < 0.001 1.24 (1.12-1.38) < 0.001 
Secondary Efficacy Outcomes     
Likelihood Earlier Live Weaning  
from Mechanical Ventilatory 
Support 
1.21 (1.09-1.35) < 0.001 1.19 (1.07-1.32)   0.001 
Renal Replacement Therapy 0.49 (0.24- 0.97) 0.03 0.52 (0.25-1.03) 0.06 
Likelihood Earlier Live Hospital 
Discharge  
1.22 (1.09-1.36) < 0.001 1.19 (1.07-1.33)   0.001 
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Supplementary table 8. Highest plasma concentrations during PICU stay for markers of liver 
dysfunction and inflammation. Mean plasma glucose concentration during PICU stay 
 
 
 
PN=Parenteral Nutrition, PICU=Pediatric Intensive Care Unit, SEM= Standard Error of the Mean, GGT= 
Gamma-Glutamyltransferase, ALT= Alanine Aminotransferase, AST= Aspartate Aminotransferase, 
CRP= C-reactive protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Early PN Late PN P-value 
Highest plasma concentration during PICU stay  N=723 N=717  
Liver dysfunction - mean (SEM)    
    Highest plasma bilirubin – mg/dL (N = 1258) 1.6 (0.1) 1.9 (0.2) 0.006 
    Highest plasma Alkaline Phosphatase (N=1231) 194 (5) 181 (6) <0.001 
    Highest plasma GGT – IU/L (N = 1221) 85 (7) 62 (5) 0.003 
    Highest plasma ALT – IU/L (N = 1266) 85 (9) 118 (20) 0.89 
    Highest plasma AST – IU/L (N = 1264) 202 (28) 271 (48) 0.87 
Inflammation- - mean (SEM)    
    Highest plasma CRP – mg/L (N = 1303) 86 (4) 93 (4) 0.07 
Mean plasma glucose – mg/dL (N= 1391) 117 (1.5) 100 (1.2) <0.001 
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8. General Conclusions and Perspectives 
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The central research question of this PhD project is how physicians should feed critically ill children, 
who have been admitted to the PICU. It is common sense to try enteral nutrition (EN), if the 
gastrointestinal tract can tolerate it, from admission onwards. However, EN is often insufficient to meet 
caloric needs, creating a caloric deficit. The latter builds up over time when EN is failing. To compensate 
for this caloric deficit, parenteral nutrition (PN) can be initiated. Conversely, one can ask to what extent 
a caloric deficit should be tolerated, since dosing and timing of PN in critically ill children is controversial.  
 
Through a systematic review(1) and a global survey(2) we gauged, respectively, the evidence for and 
the current practice of supplementary PN in critically ill children.  
In the systematic review we only searched for randomized controlled trials (RCT), comparing different 
dosing or timing of PN. PN was broadly defined as any type of intravenously administered 
macronutrient: carbohydrate, lipid or protein. Observational studies were not included in the systematic, 
as they cannot distinguish association from causality. Nevertheless, literature in nutrition in critically ill 
children has traditionally focused on the relationship between nutritional intake and outcome.(3) Only 6 
smaller RCT’s, comparing different dosing of macronutrients, could be identified. Besides the limited 
quantity of the evidence, RCT’s had multiple limitations. First, they all focused on intermediate or 
surrogate endpoints, instead of hard clinical outcome measures. Surrogate outcome measures, such as 
nitrogen balances and inflammatory markers, are commonly used in clinical nutritional studies.(4-6) 
While these surrogate outcome measures may give an indication on the effects of a certain treatment, 
they can be very misleading as well. This is explained by the fact that the tested treatment may have 
unnoticed side-effects that are not picked up by the surrogate endpoint. For example, studies on the use 
of steroids in acute respiratory distress syndrome (ARDS) showed improved lung compliance and better 
lung injury scores.(7, 8) However, steroids did not improve mortality in large multicenter trials.(9) 
Hyperglycemia or myopathy, known side-effects of steroid administration, may have offset its beneficial 
effects. Also, administration of high doses of growth hormone in prolonged critically ill patients increased 
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the levels of markers of anabolism, but doubled the mortality rate in these patients.(10) Second, all of 
the RCT’s were underpowered to detect differences in (surrogate) outcome measures, due to the low 
number of included patients. Third, even within the limited number of studies, the treatment 
comparisons were vastly different, looking at effects of different dosing of either proteins or lipids. 
Hence, no meaningful conclusion can be drawn from the existing literature to support any current 
practice of supplemental PN in critically ill children. This was in line with an older systematic review on 
the effects of nutritional strategies (EN and PN) on hard clinical outcome measures.(11)  
The lack of strong evidence may have contributed to the highly varying and inevitably weaker guidelines 
concerning PN for critically ill neonates to critically ill adolescents. We hypothesized that these equivocal 
guidelines result in a highly variable practice of nutritional support.(2) This was assessed in an 
international survey, distributed online through the network of The World Federation of Pediatric 
Intensive and Critical Care Societies and translated in Spanish, Chinese and French to maximize 
response rate. A point-prevalence survey on nutritional data collected in all patients present in a PICU 
on a single day was done to verify whether real life practice differed from local protocols. The most 
stunning finding from the survey was that only in half of the responding PICUs a nutritional protocol was 
in use. Calculations of energy requirements, needed to set caloric goals, are also based on different 
equations. Indirect calorimetry, the gold standard to set caloric goals according to the guidelines, was 
only used in 14% of the PICUs, which was comparable to a previous survey.(12) One can already 
deduct that, if the setting of the caloric goal differs enormously, the interpretation of caloric deficit and its 
treatment, is more difficult. All PICUs advocated early initiation of EN, while starting PN within 48 hours 
after admission was preferred in only 55% of PICUs. The point-prevalence survey nicely demonstrated 
that success of EN in critically ill children is overestimated. Lack of medical evidence may have given 
more weight to other drivers for nutritional support. For example, countries with a lower socio economic 
status already prefer late initiation of PN due to limited availability and higher cost of PN. Hence, we had 
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to conclude that even the limited available guidelines are not consistently followed and that high-quality 
evidence is urgently needed to guide clinical practice.  
 
Such a shift from almost dogmatic guidelines, based on low-quality evidence (observational studies, 
small RCTs with surrogate endpoints), to a practice based on high-quality RCTs, sufficiently powered to 
detect differences in clinical outcome measures, has taken place over the last 5 years in the adult ICU 
world. The EPaNIC trial (n=4640) was the first to study the timing to initiate PN in critical ill adults.(13) 
The other large RCTs, with slightly differing study protocols, such as the SPN(14) and the early PN 
trial(15) followed soon. While the ideal timing of supplemental PN remains uncertain in critically ill 
adults, there is now consensus that PN can be safely withheld during the first week of critical illness.(16) 
Our survey showed that only 3.5% of PICUs would wait at least 7 days to start supplemental PN.  
 
Mechanistic research from the EPaNIC trial revealed that suppression of autophagy by the early 
administration of PN may be the main driver for the harmful effects of PN.(17) Moreover, tolerating a 
caloric deficit early during critical illness did not worsen muscle wasting, but reduced ICU acquired 
muscle weakness. Muscle wasting is the primary rationale for supplemental PN when enteral nutrition 
fails. It is presumed that caloric deficits force patients to rely on their own protein reserve. Children are 
especially vulnerable as their energy stores are limited. Therefore, we wanted to investigate the role of 
ultrasonography to quantify muscle mass wasting in children.(18) Muscle wasting is a typical feature of 
ICU acquired weakness, which is a combination of critical illness polyneuropathy and critical illness 
myopathy.(19, 20) Its presentation is typically symmetrical and affects mostly the proximal limbs and the 
respiratory muscles. In adults the Medical Research Council (MRC) sum score is used to quantify 
muscle weakness with good reproducibility. However, this volitional measurement is only possible in 
non-sedated and cooperative patients. In children aged less than 6 years not a single strength 
measurement has been validated.(21) Electrophysiological testing, including electromyography and 
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nerve conduction studies, have been proposed.(22) This is however time consuming, not readily 
available in most hospitals, not standardized in children and often not feasible. An alternative technical 
diagnostic for muscle wasting in ICU is ultrasonography of skeletal muscle, has been validated in adult 
ICU patients.(23, 24) Therefore we investigated whether ultrasonography might be useful to detect 
muscle mass reduction in children and this in comparison with adults. Muscle thickness of the m 
quadriceps in critically ill adults and children was tested by two independent investigators. 
Ultrasonographical measurement of muscle thickness in critically ill children can easily be done in 
sedated critically ill children and adults with low inter-observer variability. However, the moderate 
accuracy and high intra-observer variability do not allow reliably detecting a decrease of less than 30% 
in muscle thickness in the pediatric ICU population. In adults we found acceptable inter- and intra-
observer variability, in line with other publications.(25, 26) Further research is necessary to optimize 
ultrasonography protocols to diagnose muscle wasting in critically ill children. It is nonetheless important 
not to focus only on the muscle mass reduction as we know from the adult population the quality of the 
muscle tissue is more important for muscle strength than the quantity.(27) Hence ultrasonographical 
assessment of muscle quality may be a better marker for muscle weakness.(28) In our study population 
the images obtained from those patients who were the sickest and admitted for a longer period were 
totally different. In these patients it was far more difficult to distinguish the individual components, 
adipose tissue, muscle and subcutis. Further developments in ultrasonography could help the clinician 
to identify the patients at risk and whether a certain type of nutritional support is beneficial in terms of 
muscle quality. 
 
In the third part of my PhD project we examined whether a strategy of withholding PN during the first 
week of critical illness is superior to strategy of early initiation of PN when enteral nutrition is insufficient 
to compensate the caloric deficit. During a period of 3 years we included 1440 patients (term newborns 
to 17 years old) in the PEPaNIC trial. The PEPaNIC trial was sufficiently powered to detect differences 
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in clinical outcome measures (incidence of new infections in PICU and the length of stay in PICU). Also 
its statistical analysis plan was published in advance.  
All patients admitted to the PICU in the three participating centres (Dept Intensive Care Medicine 
Leuven, Sophia Children’s Hospital Rotterdam and Stollery Children’s Hospital Edmonton in Canada) 
were assessed for eligibility on a daily basis. The high PELOD and PRISM scores indicate that those 
patients who really needed a nutritional plan were included in the trial. The intervention of late PN was 
exactly similar in the three centers; this was compared with the current standard nutritional support of 
early PN. The current early PN strategy obviously differed among the 3 centers. The latter underscores 
the external validity of the trial. The initiation and augmentation of enteral nutrition was similar in both 
groups. The two randomization groups were nicely balanced, but moreover they represented the wide 
range of critically ill children concerning admission diagnosis and age. The benefits of late PN were 
unexpectedly overwhelming. The two primary outcome measures, namely the incidence in new infection 
and duration of stay, which are a reflection of enhanced recovery, were both markedly reduced. The 
benefits of late PN were present across all predefined risk factors (PELOD-score, center, age, nutritional 
risk score and admission diagnosis). This underpins the robustness of the findings and the broad 
applicability of the late PN strategy. To ascertain the correctness of the study findings, both unadjusted 
and risk factor adjusted comparisons were done, taking death as a competing risk for earlier discharge 
or absence of new infection. This was to exclude that new infections were avoided or length of stay was 
shortened because the patient died. The change of earlier discharge from the PICU and from the index 
hospital was significantly different and this effect even remained in the transferral hospital. Such a 
stringent methodology for clinical trials in nutritional research in critically ill children has not been used 
before. The positive effects of late PN are more pronounced compared to the adult EPaNIC trial.(13) 
This may be due to the fact that the PICU population is in a way a “cleaner” population. Critically ill 
children mostly do not suffer from long existing chronic medical diseases.  
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Interestingly inflammation, reflected in higher CRP levels, was more pronounced in the late PN group, 
while they had fewer infections. So in essence the inflammatory response is better preserved in a 
hypocaloric condition, leading to fewer infections. This could underlie the concept that late PN preserves 
autophagy, which is an essential part of the innate immunity.(29-31) Neonates live on autophagy, 
because they need the process to go from constant feeding intra-uterine to intermittent feeding once 
they are born.(32) Newborn animals in which autophagy is eliminated die.(33) This is in line with the 
finding that the neonates in the PEPaNIC trial benefited the most from a late PN strategy.  
 
As usual, new findings from clinical studies raise new questions and future perspectives.  
From the PEPaNIC trial it is clear that closing the caloric deficit early by the administration of PN, is 
harmful. Post-hoc analyses of the EPaNIC trial in critically ill patients revealed that there is dose-
dependency of the harmful effects of PN.(34) In patients with contraindications for EN, late PN had the 
strongest treatment effect.(13) The lower doses of macronutrients were associated with faster recovery. 
Whether this dose-dependency is also present in critically ill children is unclear.  
The EPaNIC post-hoc analyses also hinted that the amount of amino acids/proteins may be responsible 
for the delayed recovery in critically ill adults. This may be contra-intuitive as proteins are regarded as 
essential to maintain muscle mass. However, proteins are also strong suppressors of autophagy, which 
may reduce the quality of skeletal muscle. Isotope studies in critically ill adolescents showed that high 
protein intake increased gluconeogenesis and lipolysis.(35) Increased glucose production and lipolysis 
my worsen insulin resistance and hyperglycemia, which are also linked with poor outcome. The 
PEPaNIC RCT was not set up to evaluate the  role of the individual macronutrients. However, as the 
control group of early PN differed among the three centers, post-hoc analyses may give an indication 
whether carbohydrates, lipids or proteins are the main culprits for delayed recovery with early PN.  
In our trial we only focussed on PN, the question raises if early EN is also harmful. This is even more 
controversial. Obviously when a child can be fed enterally, physicians will always do so and should do; 
  
172 
 
as this will be in line with the severity of illness. The sicker a child is the more difficult it is to feed it. But 
what to do with prokinetics? Should we start them at all? The children with the highest nutritional risk 
benefitted the most from late PN. Moreover in the adult EPaNIC trial late PN was even more beneficial 
in the group of patients who could not be fed enterally.(13) Additionally, large RCTs such as the EDEN 
and the CALORIES trial demonstrated that an aggressive EN strategy is certainly not beneficial for the 
critically ill adult.(36, 37) In my opinion this all points in one direction, namely that we do not need to 
force enteral nutrition in our patients. 
 
Conducting a large, international, multicenter trial with hard clinical outcomes like the PEPaNIC is a true 
challenge. Highly standardized protocols with a clear difference between the control group and the 
intervention group are the necessary foundations of the trial. The whole medical, nursing and dieticians’ 
team has to be willing to make a success of the trial, through strict protocol compliance and direct 
communication with the trial coordinators. One can only be willing to make it a success of something if 
he or she understands the essence of the research question and hence the need of the trial. Frequent 
presentations to bedside doctors and nurses to familiarize them with the protocol are indispensable. In 
order to prevent selection bias the trial coordinators need to screen the entire population to assure that 
every patient who fits the inclusion criteria, is approached for consent. Asking the consent is time 
consuming but crucial, as parents have many questions about the trial but also about their child’s stay in 
intensive care. So in each participating center there has to be a local trial coordinator who is at all time 
in contact with the central trial coordinator. In essence the success of the multicentre aspect depends on 
the strength of the alliance between the different partners and this on all levels.  
In contrast with our PEPaNIC trial, in the past 4 years there have been many multicenter trials in the 
adult ICU published that are neutral. A neutral trial can be very valuable, provided that the trial is well 
conducted. Poor protocol compliance, non-realistic power calculations and poor inclusion rate per center 
are the main reasons of failure for many trials. For the community and medicine in se it is however 
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crucial that well designed multicenter trials with enough statistical power and appropriate outcome 
measures provide the necessary medical evidence to improve standard of care worldwide. 
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Summary 
 
Nutrition for children is needed for maintaining all the processes in the body and for growth. 
Nutrition can be subdivided in macronutrients and micronutrients. Macronutrients comprise proteins, 
lipids and carbohydrates. Micronutrients encompass trace elements and vitamins. 
 
When a child is admitted to the PICU it is often not capable to eat. Therefore physicians initiate artificial 
nutrition. This can be done through a gastric tube which is the most natural way of providing nutrition. 
However caloric targets are often not reached due to gastrointestinal intolerance. To meet the caloric 
needs, parenteral nutrition, which is given intravenously, is often started.  
 
When and how much parenteral nutrition should be given, is the question of this PhD. We did a 
systematic review to gather all scientific evidence, supporting the dosing and timing of PN. We only 
found 6 smaller randomized controlled trials, looking at surrogate endpoints such as nitrogen balances 
and inflammation to evaluate the effects of different PN regimens. All studies were statistically 
underpowered due to their small size. Hence, there was no scientific evidence at all to guide the 
initiation, dosing of supplemental PN. We hypothesized that the lack of sound evidence should result in 
a very variable daily practice worldwide. We therefore performed an international survey. Results were 
striking. In half of the pediatric intensive care units there was no nutritional protocol. Dosing and timing 
were also very variable. Moreover, as PN is expensive, countries with a lower socio economic status 
reported more frequently late initiation of PN. 
 
To evaluate whether PN should be started within the first week of critical illness, we conducted a large 
international randomized controlled trial. During 3 years 1440 children were included in the PEPaNIC 
trial, at 3 study sites: Leuven, Rotterdam, NL and Edmonton, Canada. The current practice of supplying 
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PN, which was slightly different in each center, was compared with the same intervention, namely no 
PN during the first week of critical illness and only providing maintenance fluid.  
The incidence of new infection and duration of stay were markedly reduced when PN was omitted 
during the first week of pediatric critical illness. The results where independent of predefined risk factors, 
such as severity of illness, reason for admission, age and study center. When you initiate PN during the 
first week of critical illness, you impair the child’s chances of recovery. One might have concerns that 
not giving PN to the most vulnerable children, namely neonates and the children with a high nutritional 
risk, would harm them. Surprisingly the beneficial effects of not giving PN to these children were even 
more pronounced.  
 
How can this be explained? One of the responsible mechanism is autophagy. It is an essential part of 
the innate immune system and also responsible for quality control in cells. Suppression of autophagy, 
leading to defective clearance of damaged cell organelles, could be the driver behind the clinical effects 
of the trial. 
 
Not substituting the caloric deficit could force patients to rely on their own reserves. Clinically this would 
result in slower recovery and loss of muscle mass tissue, as this a major source of proteins. With our 
trial we proved that recovery is enhanced instead of hampered. To analyze muscle mass in critically ill 
adults, ultrasonography is an accessible and easy tool. However, in critically ill children this technique 
has not been validated. Therefore, we investigated whether ultrasonography is reliable to use in critically 
ill children. Our results showed that the intra-observer variability - the difference between two 
measurements done by the same investigator - was too high when taking into account the expected loss 
of muscle mass. In my opinion, future research on the diagnosis of muscle weakness should also look 
at the quality of the muscle instead of the quantity. As we know from adult studies that apart from the 
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loss itself it is especially the changes in muscle tissue quality that are responsible for the resulting 
muscle weakness. 
 
In conclusion we advise to tolerate a caloric deficit during the first week of critical illness in PICU, when 
enteral nutrition is insufficient. 
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Samenvatting 
 
Kinderen hebben voeding nodig om in leven te blijven en te groeien. Voeding wordt onderverdeeld in 
macronutriënten en micronutriënten. De macronutriënten bestaan uit eiwitten, suikers en vetten. 
Vitaminen en sporenelementen vormen op hun beurt de micronutriënten.   
 
Wanneer een kritiek ziek kind opgenomen wordt op intensieve zorgen is het vaak niet in staat om te 
eten. Daarom zullen kinderintensivisten kunstmatige voeding starten. Vooreerst door sondevoeding, bij 
het jonge kind flesvoeding of borstvoeding toe te dienen via de maagsonde hetgeen we enterale 
voeding noemen. Tijdens kritieke ziekte wordt deze enterale voeding echter vaak minder goed 
verdragen, hetgeen ervoor zorgt dat een calorisch deficit ontstaat. Om dit deficit te vermijden, wordt er 
vaak parenterale voeding gestart dewelke gegeven wordt via een intravenueze lijn in een grote 
lichaamsader. 
 
Wanneer deze parenterale voeding dient gestart te worden en hoeveel er gegeven moet worden, vormt 
het onderwerp van dit doctoraat. Om inzicht te krijgen in de huidige wetenschappelijke evidentie omtrent 
dit onderwerp, hebben we op een systematische wijze de alle systematische en gerandomiseerde trials 
(RCT) verzameld in een systematic review. We konden slechts 6 RCT’s weerhouden die allen 
methodologisch zwak waren. Op basis van deze RCT’s kunnen dan ook op geen enkele wijze  
gevalideerde richtlijnen aangaande dit onderwerp geformuleerd worden. Om na te gaan of dit gebrek 
aan duidelijke richtlijnen aanleiding geeft tot een zeer variabele praktijk wereldwijd, deden we een 
enquête omtrent voeding op kinderintensieve. We kregen antwoord vanuit 52 landen en dit van 156 
kinderintensieve afdelingen. De resultaten gaven aan dat de variabiliteit aangaande voedingsbeleid op 
kinderintesieve bijzonder groot is en dat zelfs de helft van de centra toegaf dat ze geen 
voedingsprotocol voorhanden hadden.  
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Om dus een gefundeerd antwoord te kunnen verschaffen op de vraag of parenterale voeding moet 
gestart worden gedurende de eerste week van kritieke ziekte bij kinderen, voerden we een grote 
internationale studie uit in Leuven, Rotterdam en Edmonton. In totaal werden over een periode van 3 
jaar 1440 kinderen geïncludeerd. Het huidige voedingsbeleid van de drie centra, die uiteraard onderling 
verschilden, werden vergelijken met één en dezelfde interventie groep. Deze interventie bestond erin 
om geen parenterale voeding tijdens de eerste week van kritieke ziekte te geven en enkel 
onderhoudsvocht toe te dienen. De resultaten van deze RCT zijn opzienbarend. De incidentie van 
nieuwe infecties evenals de verblijfsduur op kinderintensieve en in het ziekenhuis werden aanzienlijk 
verminderd. Dit effect was onafhankelijk van verscheidene risicofactoren waaronder bv het centrum, 
hetgeen aangeeft dat het schadelijk is om parenterale voeding toe te dienen tijdens de eerste week van 
kritieke ziekte. Bij kinderen met een hoog risico op ondervoeding en de neonaten was dit schadelijk 
effect zelfs nog meer uitgesproken. Hoe kan men dit verklaren? Een van de mogelijke mechanismen is 
autofagie. Dit is een essentieel onderdeel van de aangeboren immuniteit en vitaal voor de controle van 
de cel kwaliteit. Onderdrukken van autofagie kan deels de klinische effecten vastgesteld in onze studie 
verklaren. 
 
Het toelaten van een calorisch deficit kan patiënten forceren om terug te vallen op hun eigen endogene 
reserves. Klinisch zou dit resulteren in een vertraagd herstel een verlies aan spiermassa. We toonden 
echter aan dat het herstel werd bespoedigd door geen PN te starten. Bij volwassenen is reeds 
aangetoond dat echografie betrouwbaar is om spiermassa verlies te diagnosticeren. Bij kinderen werd 
dit bij ons weten nog nooit nagegaan. Daarom hebben we dit op systematische wijze onderzocht bij 
volwassenen en kinderen. De resultaten wijzen uit dat de intra-observer variabiliteit te groot is om het 
verwachte spiermassa verlies te kunnen diagnosticeren. Met ander woorden het verschil tussen twee 
opeenvolgende metingen uitgevoerd door de dezelfde onderzoeker zijn te groot in vergelijking met de 
verwachte spiermassareductie om de techniek toe te passen bij kinderen.  
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Bijkomend onderzoek is dus nog nodig om de massa evenals kwaliteit van het spierweefsel op 
eenvoudige wijze te kunnen analyseren. Gezien onderzoek bij volwassenen heeft aangetoond het niet 
zozeer het verlies van spiermassa maar wel de kwaliteit van het resterende spierweefsel bepalend is 
naar de resterende spiersterkte.  
 
Als conclusie van dit doctoraat adviseren we om geen parenterale voeding te starten bij kinderen op 
intensieve zorgen gedurende de eerste week van kritieke ziekte. 
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